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Heart failure is a progressive disease in which the heart is no longer able to pump 
sufficient amounts of blood to the body.  Over six million Americans currently suffer 
from heart failure, and although pharmacological and surgical therapies continue to 
improve, about 50% of people with heart failure still die within five years of diagnosis. 
As the human heart fails, many structural, cellular and molecular alterations occur 
that contribute to the decrease in heart function.  It has been well-established that some of 
these alterations are the result of sympathetic nervous system hyperactivation, and 
decreasing sympathetic input with a beta blocker or left ventricular assist device 
improves clinical status and also reverses the cellular and molecular alterations associated 
with heart failure.  We hypothesized that heart failure patients could be trained with 
biofeedback and that this method of sympathetic nervous system regulation would also 
produce myocardial remodeling in the direction of recovery. 
 viii
To test this hypothesis, twenty end-stage heart failure patients listed for heart 
transplantation at the Cleveland Clinic received eight sessions of biofeedback-assisted 
stress management training.  After biofeedback training, at the time of heart 
transplantation, explanted hearts were transported to the laboratory to study the heart 
failure phenotype.  Data were compared to samples of non-failing, failing (negative 
control), and LVAD-supported failing (positive control) hearts. 
 We found that the inotropic response of left ventricular trabecular muscles to 
sympathetic nervous stimulation recovered in patients who received biofeedback training 
such that it was not significantly different from the non-failing average.  Normalization of 
both rate of contraction and relaxation were also shown in the biofeedback group.  Beta 
adrenergic receptor density was significantly lower in the biofeedback group relative to 
non-failing hearts, however significant recovery was shown in some patients.  Western 
Blot analysis of calcium cycling proteins showed that SERCA and NCX expression in the 
biofeedback group was at the same level as the non-failing group, and a significant 
decrease in RYR expression was shown in the biofeedback hearts.  These data suggest 
that biofeedback produces some remodeling of the heart failure phenotype, in the 








TABLE OF CONTENTS 
 
Page 
ABSTRACT ………………………………………………………………………… vii 
LIST OF TABLES ……..…………………………………………………………… xiii 
LIST OF FIGURES …….…………………………………………………………… xv 
CHAPTER 
 I.  INTRODUCTION …………………………………………………………… 1 
 1.1 Normal Cardiac Physiology ………………………………………… 2 
 Excitation-Contraction Coupling and Calcium Cycling ……….. 2 
 The Beta-Adrenergic Signaling Pathway ………………………. 3 
 The Muscarinic Signaling Pathways …………………………… 7 
 1.2 Heart Failure: A Process of Remodeling …………………………… 8 
 1.3 The Autonomic Nervous System in Heart Failure …………………. 11 
 1.4 The Reversibility of Heart Failure …………………………………. 12 
 1.5 Biofeedback ………………………………………………………… 14 
  Heart Rate Variability ………………………………………….. 16 
 1.6 Summary and Hypothesis ………………………………………….. 17 
 II.  METHODS ………………………………………………………………….. 19 
2.1 Patient Selection ……………………………………………………. 19 
2.2 Biofeedback Protocol ………………………………………………. 20 
 Sensors and Screens ……………………………………………. 20 
 Session Outline ………………………………………………… 24 
 x
 Homework ……………………………………………………… 31 
 Quality of Life Assessment ……………………………………. 31 
 Subjective Data ………………………………………………… 31 
 Clinical Assessment ……………………………………………. 33 
 2.3 Human Heart Tissue Procurement …………………………………. 33 
 2.4 Cardiac Muscle Function …………………………………………… 33 
 2.5 Sarcolemmal Membrane Isolation and Purification ……………….. 36 
 2.6 Measure of Total Protein for Receptor Density Analysis ………….. 39 
 2.7 Total Beta-Adrenergic Receptor Density ………………………….. 39 
 2.8 Total Muscarinic Receptor Density ………………………………… 41 
 2.9 Tissue Homogenization for Western Blotting ……………………… 43 
 2.10 Measurement of Total Protein for Western Blotting ………………. 44 
 2.11 Western Blotting to Measure Calcium Cycling Proteins …………… 44 
 2.12 Data Analysis ……………………………………………………….. 45 
  Biofeedback, Quality of Life and Clinical Data ……………….. 45 
  Removing Artifact from Heart Rate Variability Data ………….. 47 
  Biological Data …………………………………………………. 47 
  Correlation Data ……………………………………………….. 48 
 III. RESULTS …………………………………………………………………… 49 
 3.1 Biofeedback Data ………………………………………………..… 49 
  Respiration Rate ……………………………………………….. 49 
    Inpatients vs. Outpatients ………………………………… 53 
  Digital Peripheral Temperature ………………………………… 58 
 xi
    Inpatients vs. Outpatients ………………………………… 58 
   Skin Conductance …………………………………………….... 62 
   Heart Rate Variability …………………………………………... 62 
    Inpatients vs. Outpatients ………………………………… 65 
   Psychophysiologic Reactivity and Recovery ………………....... 65 
    Inpatients vs. Outpatients ………………………………… 73 
 3.2 Homework Data ……………………………………………………. 73 
 3.3 Quality of Life Data ……………………………………………....... 77 
   SF-36 …………………………………………………………… 77 
    Inpatients vs. Outpatients ………………………………… 77 
   Kansas City Cardiomyopathy Questionnaire ………………...… 83 
    Inpatients vs. Outpatients ………………………………… 83 
3.4 Subjective Data …………………………………………………….. 83 
   Inpatients vs. Outpatients ………………………………………. 89 
3.5 Clinical Data ……………………………………………………….. 93 
   Six Minute Walk Test ………………………………………….. 93 
   Plasma Norepinephrine ………………………………………… 93 
3.6 Biological Data …………………………………………………….. 98 
   Muscle Function ……………………………………………….. 98 
   Beta-Adrenergic Receptors ……………………………………. 107 
   Muscarinic Receptors ………………………………………….. 111 
   Calcium Cycling Proteins ………………………………………. 115 
3.7 Correlation Data ……………………………………………………. 119 
 xii
 IV. DISCUSSION ………………………………………………………………. 127 
 4.1 Biofeedback in End-Stage Heart Failure Patients ………………….. 127 
   Respiration Rate ……………………………………………….. 127 
   Digital Peripheral Temperature ………………………………… 128 
   Heart Rate Variability ………………………………………….. 130 
   Psychophysiologic Reactivity and Recovery ………………....... 131 
   Homework ……………………………………………………… 132 
   Subjective Data ………………………………………………… 133 
   Inpatients vs. Outpatients ………………………………………. 133 
4.2 The Effect of Biofeedback on Quality of Life ……………………… 136 
4.3 The Effect of Biofeedback on Clinical Course …………………….. 137 
4.4 The Effect of Biofeedback on Myocardial Remodeling ……………. 138 
   Muscle Function ……………………………………………….. 139 
   Beta-Adrenergic Receptors ……………………………………. 141 
   Muscarinic Receptors ………………………………………….. 143 
   Calcium Cycling Proteins ………………………………………. 145 
4.5 Correlation Data ……………………………………………………. 147 
4.6 Summary ………………………………………………………........ 149 
4.7 Future Directions …………………………………………………… 149 





LIST OF TABLES 
 
Table Description Page 
 I. Physiologic Signals When a Person is Relaxed……………………………... 23 
 II. Western Blot Antibody Conditions…………………………………………. 46 
 III. Demographics of the 35 End-Stage Heart Failure Patients Enrolled in the 
   Study …………………………………………………………………. 50 
 IV. Demographics of the 20 End-Stage Heart Failure Patients Who Completed 
   All 8 Sessions of Biofeedback………………………………………… 51 
 V. Clinical Analysis of Respiration Rate Before and After Biofeedback 
   Training …………………………………………………………….... 56 
 VI. Respiration Rate Percentage Counter Summary for Inpatients and 
   Outpatients …………………………………………………………… 60 
 VII. Trends in Cardiovascular Reactivity ………………………………………. 71 
 VIII. Number of Homework Sheets Turned In …………………………………. 76 
 IX. Aggregate Scores on SF-36 Before and After Biofeedback Training …….. 79 
 X. Clinical Analysis of SF-36 Aggregate Scores …………………………….. 82 
 XI. Aggregate Scores on KCCM Before and After Biofeedback Training ..…. 84 
 XII. Clinical Analysis of KCCM Aggregate Scores ……………………………. 87 
 XIII. Data Collected on All Patients Enrolled in the Study …………………….. 94 
 XIV. Detailed Patient Demographics for Biological Data ………………………. 100 
 XV. Summarized Patient Demographics for Biological Data ………………….. 101 
 XVI. Contractile Parameters at Baseline ………………………………………... 103 
 xiv
Table Description Page 
XVII. Biofeedback versus Biology Correlation Data …………………………… 121 
XVIII. Transplant Wait Time …………………………………………………..… 125 





















LIST OF FIGURES 
 
Figure Description Page 
 1. Calcium Cycling in the Cardiac Myocyte ………………………………… 4 
 2. Beta-Adrenergic Signaling Pathway in the Cardiac Myocyte ……………. 6 
 3. Muscarinic Signaling Pathway in the Cardiac Myocyte ………………….. 9 
 4. Left Ventricular Assist Device ……………………………………………. 13 
 5. Heart Rate Variability ……………………………………………………… 18 
 6. Biofeedback Sensors ………………………………………………………. 22 
 7. Respiration Rate Patient Training Screen …………………………………. 25 
 8. Digital Peripheral Temperature Patient Training Screen …………………. 26 
 9. Skin Conductance Patient Training Screen ………………………………... 27 
 10. Heart Rate Variability Patient Training Screen ……………………………. 28 
 11. Biofeedback Therapist / Technician Screen ………………………………. 29 
 12. Schematic Outline of Biofeedback Sessions ………………………………. 30 
 13. Daily Record Sheet …………………………………………………..…… 32 
 14. Muscle Bath Set-Up ………………………………………………………. 35 
 15. Individual Muscle Contraction Showing 6 Contractile Parameters ………. 37 
 16. Typical Saturation Curve and Lineweaver-Burk Plot ……………………. 42 
 17. Average Respiration Rate During Self-Relaxation Before and After 
   Biofeedback Training ……………………………………………….. 52 
 18. Average Respiration Rate during Self-Relaxation Across All Biofeedback 
   Sessions …………………………………………………………..…. 54 
 xvi
Figure Description Page 
 19. Percentage of Relaxation Time Patients Spent Breathing at Lower Rates 
   Before and After Biofeedback Training .……………………………. 55 
 20. Average Respiration Rate during Self-Relaxation Before and After 
   Biofeedback Training in Inpatients and Outpatients ………………… 57 
 21. Average Respiration Rate during Self-Relaxation Across All Biofeedback 
   Sessions in Inpatients and Outpatients ………………………………. 59 
 22. Average Finger Temperature Following and Throughout Biofeedback 
   Training ……………………………………………………………… 61 
 23. Average Skin Conductance During Self-Relaxation Across All 
   Biofeedback Sessions ……………………………………………….. 63 
 24. Average SDNN During Self-Relaxation Before and After Biofeedback 
   Training ……………………………………………………………… 64 
 25. Average SDNN During Self-Relaxation Across All Biofeedback Sessions  66 
 26. Average SDNN During Self-Relaxation Before and After Biofeedback 
   Training in Inpatients and Outpatients ……………………………… 67 
 27. Average SDNN During Self-Relaxation Across All Biofeedback Sessions 
    in Inpatients and Outpatients ………………………………………… 68 
 28. Average Heart Rate During 5-Minute Baseline in Psychophysiologic 
   Assessment Before and After Biofeedback Training ……………….. 69 
 29. Overall Cardiovascular Reactivity to Mental Stress Following 
   Biofeedback Training ……………………………………………….. 72 
 
 xvii
Figure Description Page 
 30. Overall Cardiovascular Reactivity from Mental Stress Following 
   from Mental Stress Following Biofeedback Training ………………. 74 
 31. Overall Cardiovascular Reactivity and Recovery Before and After 
   Biofeedback Training in Inpatients and Outpatients ………………… 75 
 32. Quartile Distribution of Homework Turned In by Inpatients and 
   Outpatients …………………………………………………………… 78 
 33. SF-36 Social Functioning Aggregate Score Before and After Biofeedback    
   Training in Inpatients and Outpatients  ………………………………. 80 
 34. SF-36 General Health Aggregate Score Before and After Biofeedback  
   Training in Inpatients and Outpatients ………………………………. 81 
 35. KCCM Quality of Life Aggregate Score Before and After Biofeedback 
   Training in Inpatients and Outpatients ………………………………. 85 
 36. KCCM Clinical Summary Aggregate Score Before and After Biofeedback   
   Training in Inpatients and Outpatients ………………………………. 86 
 37. Self-Reported Relaxation Level Throughout Psychophysiologic 
   Assessment Before and After Biofeedback Training  ……………….. 88 
 38. Self-Reported Relaxation Level for Stressful and Relaxing 
   Psychophysiologic Assessment Activities Before and After  
   Biofeedback Training  ……………………………………………….. 90 
 39. Average Self-Reported Relaxation Level Throughout Training Sessions ... 91 
 40. Average Self-Reported Mood Throughout Training Sessions …………….. 92 
 
 xviii
Figure Description Page 
 41. Average Six Minute Walk Distance Before and After Biofeedback 
Training ……………………………………………………………… 95 
 42. Individual Six Minute Walk Distance Before and After Biofeedback 
Training ……………………………………………………………… 96 
 43. Average Plasma Norepinephrine Level Before and After Biofeedback 
Training ………………………………………………………………. 97 
 44. Individual Plasma Norepinephrine Level Before and After Biofeedback 
Training ………………………………………………………………. 99 
 45. Resting Tension Following Addition of Isoproterenol ……………………. 104 
 46. Developed Tension Following Addition of Isoproterenol …………………. 105 
 47. Time to Peak Tension Following Addition of Isoproterenol ………………. 106 
 48. Time to Half Relaxation Following Addition of Isoproterenol …………… 108 
 49. Peak Rate of Tension Rise Following Addition of Isoproterenol …………. 109 
 50. Peak Rate of Tension Fall Following Addition of Isoproterenol ………….. 110 
 51. Beta-Adrenergic Receptor Density ………………………………………... 112 
 52. Binding Affinity for Beta-Adrenergic Receptors ………………………….. 113 
 53. Muscarinic Receptor Density ……………………………………………… 114 
 54. Binding Affinity for Muscarinic Receptors ……………………………….. 116 
 55. SERCA / CALQ ……………..……………………………………………. 117 
 56. NCX / CALQ ……………………………………………………………… 118 
 57. RYR / CALQ ……………………………………………………………… 120 
 
 xix
Figure Description Page 
 58. Relationship between Respiration Rate and Ryanodine Receptor Protein 
Expression …………………………………………………………… 122 
 59. Relationship between Respiration Rate and Developed Tension Response 











 Cardiovascular disease is the number one killer of men and women in the United 
States today, accounting for approximately 55% of all deaths.1  Nearly 83 million 
Americans have one or more types of cardiovascular disease, including high blood 
pressure, coronary artery disease, angina pectoris, stroke, or congenital cardiovascular 
defects.1  Although each form of cardiovascular disease represents a different etiology, 
the end-stage of all cardiovascular diseases is heart failure. 
Heart failure occurs when the heart is no longer able to adequately pump blood to 
the body.  While pharmacological therapies such as beta blockers and angiotensin 
converting enzyme inhibitors have been proven to alleviate the symptoms of this disease, 
heart failure continues to progress in patients receiving optimal pharmacological 
treatment,75 and therefore heart transplantation is still the only option for long-term 
success.94  Unfortunately, the number of donor hearts is limited, leveling off at about 
2,300 per year,117 and therefore many patients will succumb to the disease before a donor 
heart becomes available.  Because of this, it is necessary to explore alternative or 
 2
adjunctive therapies to ameliorate disease progression or to provide a positive means for 
patients to cope with the disease sequelae.  This project investigated the efficacy of 
biofeedback-assisted stress management training to reverse myocardial remodeling in 
patients with end-stage heart failure.   
 
1.1  Normal Cardiac Physiology 
Before introducing how the heart remodels during failure, it is important to note 
how the heart contracts in a normal, non-diseased state. 
 
Excitation-Contraction Coupling and Calcium Cycling 
 Excitation-contraction coupling is a series of biochemical processes that converts 
electrical signals into mechanical signals through elevation of intracellular calcium.9  
Electrical activity is initiated when a specialized bundle of cells in the upper part of the 
right atrium of the heart, called the sinoatrial node, initiates a wave of depolarization that 
is propagated throughout the myocardium in an organized sequence, ultimately reaching 
the atrial and ventricular myocytes.  This cardiac action potential depolarizes the myocyte 
sarcolemma, allowing calcium to enter the cell through L-type calcium channels.  This 
small inward flux of calcium triggers a much larger release of calcium from inside the 
cell in a process called “calcium-induced calcium release.”  Specifically, the 
sarcoendoplasmic reticulum (SR), the main site of calcium storage in the cell, releases 
calcium through a calcium-sensitive channel known as the ryanodine receptor (RYR).  
This large release of calcium into the cytosol binds to the myofilaments and activates 
actin-myosin cross-bridging and cardiac muscle contraction.9,8,49   
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Because an increase in intracellular calcium is necessary for cardiac muscle to 
contract, there must be a decline in intracellular calcium concentration in order for 
cardiac muscle to relax.  In cardiomyocyte relaxation, calcium is released from the 
myofilaments and is either pumped into the SR or extracted from the cell.  Most free 
intracellular calcium (about 80%) is taken back up into the SR via the sarcoendoplasmic 
reticulum calcium ATP-ase (SERCA).  Under baseline conditions, SERCA activity is 
partially inhibited by a calcium regulatory protein called phospholamban (PLB).  When 
increased cardiac contractility is needed (such as during exercise or other sympathetic 
activation), PLB is phosphorylated and dissociates from SERCA, removing its inhibition 
and allowing SERCA to more rapidly remove calcium from the cytosol.  For every 
molecule of ATP consumed, SERCA pumps two calcium back into the SR.  Once inside 
the SR, calcium binds to calsequestrin (CALQ), one of several calcium-binding proteins 
that holds calcium in the SR until the next contraction.  The other 20% of intracellular 
calcium is removed from the cell via the sodium-calcium exchanger (NCX).  The NCX is 
an antiporter that brings three sodium into the cell for every calcium moved out into the 
extracellular space.  SERCA and NCX are the two major systems involved in reducing 
intracellular calcium during cardiac muscle relaxation.  Figure 1 provides and overview 
of the calcium cycling process which occurs every time the heart beats.5,6,96 
 
The Beta-Adrenergic Signaling Pathway 
 One of the major pathways existing in the heart that effects both heart rate and 
force of contraction through its effects on calcium cycling in the cardiac myocyte is the 















































Figure 1.   Calcium cycling in the cardiac myocyte. 
 
Depolarization of the sarcolemma allows calcium to enter the cell 
through L-type calcium channels (1 & 2) which triggers the release of 
a large amount of calcium from the sarcoendoplasmic reticulum (SR) 
through the ryanodine receptor (RYR) (3) and into the cytosol (4 & 5).  
This increase in intracellular calcium binds to the myofilaments (6), 
causing cardiac muscle contraction.  During relaxation, calcium is 
released from the myofilaments (7) and is pumped back into the SR 
via the sarcoendoplasmic reticulum calcium ATP-ase (SERCA) (8a) 
where it binds to calsequestrin (CALQ) until the next contraction.  
Some calcium is also extracted from the cell via that sodium-calcium 
exchanger (NCX) (8b).  Phospholamban (PLB) regulates SERCA 
activity, inhibiting it in the baseline state. 
 
(Figure 1 is modified from DM Bers, 1993.)9 
 5
increase in heart rate (chronotropy) and contractility (inotropy), as well as an increase in 
the speed of myocardial relaxation (lusitropy).115 
 The beta-adrenergic signaling pathway (illustrated in Figure 2) is activated when 
an agonist such as endogenous neurohormones epinephrine and norepinephrine, or 
isoproterenol (a synthetic analogue of norepinephrine), binds to the beta-adrenergic 
receptor on the surface of the cardiac myocyte.  This causes activation of the stimulatory 
G protein (Gs) which is linked to the enzyme adenylyl cyclase (AC).  Activation of AC 
then catalyzes the dephosphorylation of adenosine triphosphate (ATP) to form cyclic 
adenosine monophosphate (cAMP).  Acting as a second messenger, cAMP activates 
protein kinase A (PKA), which phosphorylates many intracellular proteins including the 
L-type calcium channels, myosin binding protein C (MyBP-C), troponin I (TnI), 
phospholamban, and ryanodine receptors.71,115 
 Phosphorylation of the L-type calcium channels on the sarcolemma causes a 
greater influx of calcium into the cell during depolarization.  By increasing the amount of 
intracellular calcium, more calcium is available to bind the myofilaments, and as a result, 
contractility is increased.115,126 
 Located at the level of the myofilaments, myosin binding protein C regulates the 
ATPase activity of the actin/myosin complex.  Specifically, MyBP-C reduces ATPase 
activity, serving as a “brake” on crossbridge cycling.  Phosphorylation of MyBP-C 
releases this brake, increasing the actin/myosin ATPase activity and enhancing cardiac 
contractility.33,105,115 
Also located at the level of the myofilaments, Troponin I is one of the three 
























Figure 2.   Beta-adrenergic signaling pathway in the cardiac 
myocyte. 
 
Beta-adrenergic agonists bind to beta receptors on the surface of 
cardiac myocytes, initiating an intracellular signaling cascade resulting 
in the phosphorylation of L-type calcium channels, phospholamban 
(PLB), ryanodine receptors (RYR) as well as myosin binding protein 
C and troponin I which are located at the level of the myofilaments.  
Activation of this pathway results in an increased concentration of 
intracellular calcium, ultimately causing an increase in heart rate and 
force of contraction. 
 
(Figure 2 is modified from DM Bers, 1993.)9 
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Troponin I decreases myofilament sensitivity to calcium, thereby increasing the rate at 
which calcium is released from the myofilaments.  This free calcium, now in the cytosol, 
can be pumped into the sarcoendoplasmic reticulum (via SERCA) or extracted from the 
cell (via NCX), decreasing the amount of intracellular calcium and increasing the rate of 
myocardial relaxation.105,115 
The rate of myocardial relaxation is also increased through phosphorylation of the 
regulatory protein phospholamban (PLB), located on the sarcoendoplasmic reticulum 
(SR).  At baseline, PLB retards the speed at which the sarcoendoplasmic reticulum 
calcium ATP-ase (SERCA) pumps intracellular calcium into the SR.  When PLB is 
phosphorylated, it releases this inhibition, and SERCA pumps calcium into the SR at a 
much faster rate.  This decreases intracellular calcium concentration more quickly, 
increasing the rate of myocardial relaxation.  In addition to increasing the rate of 
relaxation, phosphorylation of PLB also improves contractility.  By allowing SERCA to 
pump faster, more calcium is taken up into the SR during relaxation, and therefore more 
calcium is stored in the SR for release during the next contraction.105,115 
 In addition to an increase in SR calcium storage, beta-adrenergic signaling also 
results in a greater amount of calcium being released from the SR into the cytosol 
through phosphorylation of ryanodine receptors.  RYR phosphorylation causes these 
calcium release channels to be more sensitive to calcium-induced activation, releasing 
more calcium into the cytosol where it can bind to the myofilaments and increase cardiac 
contractility.49,77   
 
The Muscarinic Signaling Pathways 
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 Another set of pathways that exist in the heart to regulate heart rate and force of 
contraction are the muscarinic signaling pathways (Figure 3).  Muscarinic signaling 
pathways are initiated when an agonist such as acetylcholine activates muscarinic 
receptors on the cardiomyocyte cell surface.  Depending on which subtype of muscarinic 
receptor is activated, one of two different intracellular signaling cascades is initiated.20,31 
In total there are five subtypes of muscarinic receptors (named M1 – M5 based on 
the order in which they were discovered) that signal through two different pathways.  The 
even-numbered subtypes of muscarinic receptors (M2 and M4) directly antagonize the 
beta-adrenergic signaling pathway by inhibiting adenylyl cyclase through activation of 
the inhibitory G protein (Gi).  This reduces intracellular cAMP concentration and inhibits 
PKA from phosphorylating its target proteins, effectively slowing down heart rate.  In the 
presence of enhanced contractility (due to increased beta-adrenergic signaling), the 
M2/M4 signaling pathway can also cause negative inotropic effects in a phenomenon 
called “accentuated antagonism.” 20,31,68,69 
 Agonist activation of odd-numbered muscarinic receptors (M1, M3 and M5) causes 
Gq to activate phospholipase C (PLC).  PLC hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2), forming inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).  
DAG stimulates protein kinase C (PKC), and IP3 travels to the SR where it is received by 
the IP3 receptor, a calcium channel that releases calcium from the SR into the cytosol, 
increasing heart rate and force of contraction.20,31 
 
1.2  Heart Failure: A Process of Remodeling 










































































Figure 3.   Muscarinic signaling pathways in the cardiac myocyte. 
 
Muscarinic agonists bind to muscarinic receptors on the surface of 
cardiac myocytes, initiating one of two intracellular signaling 
cascades.  Even-numbered muscarinic receptor subtypes, shown in 
red, oppose the beta-adrenergic signaling pathway by inhibiting 
adenylyl cyclase (AC), ultimately inhibiting the effects of PKA 
phosphorylation and decreasing heart rate.  Odd-numbered muscarinic 
receptor subtypes, shown in blue, activate phospholipase C (PLC) 
which produces inositol 1,4,5-trisphosphate (IP3) and ultimately 
causes the opening of a calcium channel in membrane of the 
sarcoendoplasmic reticulum (SR).  Calcium flows into the cytosol 
from the SR, increasing intracellular calcium and myocardial 
contractility. 
 
(Figure 3 is modified from DM Bers, 1993.)9 
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cellular and molecular changes that manifest clinically as changes in heart size, shape and 
function.  As the human heart fails, it increases in size and mass due to an increase in 
individual cardiac myocyte length.  Ventricular chambers dilate producing thinner walls, 
and the overall geometry of the heart shifts from an ellipse to a sphere.23,24,43,101  The thin 
walls of the failing heart cannot normalize wall stress so contractile function declines.  
This decline in myocardial contractility emerges as a decrease in both left ventricular 
ejection fraction and cardiac output.16 
In addition to the structural and functional alterations associated with the failing 
heart, there are also changes at the cellular and molecular level which have come to be 
known as the heart failure phenotype.  These changes include activation of the immune 
system, as evidenced by the increased expression of inflammatory cytokines76,109,112, a 
recapitulation of the fetal gene program16, including ventricular expression of atrial 
natriuretic factor (ANF) and increased expression of both plasma ANF and B-type 
natriuretic peptide (BNP)120, and a change in myosin heavy chain isoforms72,85,88,99. 
The heart failure phenotype also includes altered calcium homeostasis due to the 
differential regulation of various calcium cycling proteins.  Specifically, SERCA 
mRNA4,36,82, protein36,52,83, and activity48,52 decrease, causing lower calcium re-uptake 
into the sarcoendoplasmic reticulum (SR) and a much lower calcium-induced calcium 
release during the next depolarization.  Phospholamban mRNA decreases, although it is 
uncertain if this is also true at the protein level.36,83  Sodium-calcium exchanger 
mRNA10,35,104, protein10,35,53,54,98, and activity10,53,98 are all upregulated in failing human 
hearts, increasing calcium extrusion from the cell.  Consistently, no changes have been 
found with respect to calsequestrin mRNA27,108 or protein27,53,83 expression in failing 
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heart tissue. 
Changes in beta-adrenergic signal transduction are also part of the heart failure 
phenotype.  In heart failure, total beta-adrenergic receptor density is decreased, and beta-
adrenergic responsiveness to catecholamines is also reduced.18,19,27,38  As a result, 
myocardial contractility increases to a lesser degree following beta-adrenergic 
stimulation in failing human hearts as compared to non-failing hearts.  In other words, the 
failing heart does not have the capacity to work harder when metabolic demands are 
placed on the body, such as during exercise18.  This is the reason why the six minute walk 
test is conducted in heart failure patients as a marker of functional exercise capacity. 
With all of these structural, cellular and molecular changes in mind, it is clear that 
the heart failure phenotype plays a pivotal role in the decreased contractility that is a 
hallmark of human heart failure. 
 
1.3  The Autonomic Nervous System in Heart Failure 
 Another hallmark of heart failure is dysregulation of the autonomic nervous 
system.  When the heart fails to pump blood effectively, inadequate tissue perfusion is 
sensed by the body, and the primary compensatory mechanism initiated to restore cardiac 
function is activation of the sympathetic nervous system (SNS).  The SNS releases 
norepinephrine (NE) which increases heart rate and enhances contractility via the beta-
adrenergic signaling pathway.  While this is a successful short-term solution, chronic 
activation of the SNS is maladaptive and generally leads to pathophysiological processes 
such as arrhythmias, plaque rupture and myocardial cell death.30,37,115  Sympathetic 
hyperactivity also leads to cardiotoxic levels of norepinephrine in the bloodstream, a 
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characteristic which has become a diagnostic of heart failure.17,18,59,62  Many studies have 
shown a correlation between circulating levels of norepinephrine and worse prognosis in 
patients with heart failure.22,25,40   
 Overactivation of the SNS alone does not produce the entire autonomic 
dysregulation in heart failure.  Sympathetic overactivity is accompanied by diminished 
parasympathetic nervous system (PNS) control of the heart.13,29,93,96  This hypoactivation 
of the PNS can have pro-inflammatory consequences that exacerbate the heart failure 
condition57,113, and some studies have even suggested that vagal withdrawal may be as 
deleterious as the overactive SNS.13  Many studies have shown that restoring a normal 
balance of sympathetic and parasympathetic nervous system activation is associated with 
improved cardiovascular health.13,39,69  
 
1.4  The Reversibility of Heart Failure 
 Until about fifteen years ago, heart failure was believed to be irreversible and 
amenable only to palliative care.  Recent research, however, in patients who have been 
hemodynamically supported with a left ventricular assist device (LVAD), has shown that 
some of the cellular and molecular alterations associated with the failing heart can be 
reversed.   
 The LVAD is a mechanical pump that is surgically implanted into the abdomen of 
many advanced heart failure patients as a bridge to cardiac transplantation (Figure 4).  
With attachments at the apex of the left ventricle and the ascending aorta, the LVAD 
performs the function of the left ventricle, pumping blood to the rest of the body so that 

























Figure 4.   The left ventricular assist device. 
 
The left ventricular assist device (LVAD) is a mechanical pump that is 
surgically implanted into the abdomen of advanced heart failure 
patients as a bridge to transplantation.  Through its attachment to the 
apex of the left ventricle, blood enters the LVAD, and the LVAD 
pumps the blood into the circulation via its attachment to the 
ascending aorta.   
 
(Figure 4 is from DJ Goldstein, 1998.)44 
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longer actively pumps blood, and it is therefore said to be unloaded. 
 Clinical studies of patients supported by an LVAD have shown improvements in 
both overall health and heart failure status41,58,67.  LVAD support has also been shown to 
“reverse remodel” the failing heart by reversing many of the cellular and molecular 
alterations that are characteristic of the heart failure phenotype.  Some of the alterations 
discovered in LVAD-supported heart failure patients include: a restoration of both whole 
heart41,67,78,89 and individual myocyte size2,28,67,89,125, improved contractile 
function5,28,41,55,89, a decrease in circulating cytokines112 and catecholamines41,58,111 as 
well as decreased plasma ANF and BNP2,122, a reversal of changes in gene 
expression5,14,97, an increase in SERCA expression5,55 as well as improvement in calcium 
cycling overall5,28,55, an increase in beta receptor density92 and responsiveness5,28,92, and 
an inactivation of some of the signaling pathways leading to the disease34,46.  Taken 
together, these findings illustrate that heart failure is not irreversible as was once 
believed.  
  
1.5  Biofeedback 
Biofeedback is a process through which individuals learn self-regulation skills 
that allow them to control their physiology for the purpose of improving health or 
performance.  It involves specialized equipment to monitor one or more physiologic 
processes and convert the signals into meaningful visual and auditory cues that are fed 
back to the client in real time.  Typically, sensors are connected to the client, measuring 
modalities such as heart rate, muscle tension and finger temperature, and the information 
is immediately displayed on a computer screen.  These physiologic processes are 
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normally under control of the autonomic, or involuntary, nervous system.  Biofeedback 
allows individuals to consciously control these involuntary physiologic processes, and in 
a clinical setting, this puts control over one’s health and well-being into the hands of the 
patients themselves.81,103 
While biofeedback can be used solely as operant conditioning, patients suffering 
from stress or a disease with a major stress component often benefit from using 
biofeedback in tandem with stress management.66  This is because acute stress is 
mediated through the autonomic nervous system, and biofeedback trains patients to 
control autonomic activation.  Specifically, psychological stress activates the sympathetic 
nervous system through what is well known as the “fight or flight” response.  
Biofeedback is therefore often used to decrease sympathetic nervous system input so that 
the parasympathetic nervous system can become more involved in regulating physiologic 
functions.87 
When biofeedback is combined with stress management, it requires a trained 
biofeedback practitioner who does more than just explaining what the biofeedback 
equipment is and how it relates to the patient’s physiology, as is done in the operant 
conditioning model.81  Here, the biofeedback practitioner must also provide stress 
management techniques and relaxation skills such as guided imagery and progressive 
muscle relaxation.  It also requires individualized training in which patients are evaluated 
for the specific vulnerabilities that lead them to hyperarousal.  This is often achieved with 
a psychophysiologic assessment in which patients are shown how their body responds to 
mental stimuli.  Baseline levels of physiologic modalities are measured before a series of 
mental stress tests and relaxation exercises.  The biofeedback practitioner then guides the 
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patient through the thought and behavior patterns that contribute to their physiological 
vulnerability.81,103  Once the mind-body connection is made, patients can differentiate 
between relaxed physiology and hyperarousal, knowing what each feels like.  The 
ultimate goal of biofeedback, therefore, is to teach patients how to self-regulate so that 
they can calm their physiology when the biofeedback equipment is not in front of them.    
 
Heart Rate Variability 
 Heart rate variability (HRV) is a physiologic modality that has come into use 
more recently as a measure of autonomic balance and cardiovascular resilience.  HRV is 
a measure of the beat-to-beat fluctuations in heart rate, which like any other stable system 
in the body, must be able to change and adapt in order to maintain homeostasis.66  The 
main inputs to the cardiovascular system that use feedback mechanisms to regulate heart 
rate are the autonomic nervous system, respiration rate, and the baroreceptors.  These 
oscillations in the system allow it to respond to stress, disease and injury, much like a 
boxer shifts his or her stance in order to respond to the next punch.   
The clinical relevance of HRV was first noticed in 1965 when a lack of HRV was 
observed prior to fetal distress.56  We now know that decreased HRV is associated with 
many diseases and disorders involving autonomic nervous system dysfunction or stress 
including cardiovascular disease, depression, anxiety, etc.60,66,116  Since then, the field has 
evolved, and in 1996, a task force was formed to determine standards of measurement, 
interpretation guidelines, and clinical applications of HRV.110 
 HRV can be measured in several ways, all beginning with an analysis of R waves 
on an electrocardiogram (EKG).  While heart rate is calculated as the number of R waves 
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per minute, HRV is a measured of the amount of time between successive R waves (the 
inter-beat interval).  Inter-beat interval (IBI) data are measured in milliseconds (msec) 
can be calculated from the heart rate by dividing 60 seconds by the heart rate (in beats per 
minute).  The resulting value is in seconds, so multiplying this value by one thousand will 
give you the IBI value in msec (Figure 5).  Because heart rate is typically reported as an 
average over time (beats per minute), it can be the same value with equal IBIs or with 
variable IBIs.  Several studies have shown that variability in the IBI (heart rate 
variability) is a marker of prognosis in cardiovascular disease, namely that greater HRV 
is a predictor of greater cardiovascular health.  It is believed that patients with end-stage 
heart failure have little or no variability in their heart rate.12,61,90 
 
1.6  Summary and Hypothesis 
As previously mentioned, (1) heart failure has structural and functional bio- 
markers that allow disease progression or recovery to be measured, (2) autonomic 
nervous system dysfunction is a hallmark of heart failure, with an increase in sympathetic 
activity and a withdrawal of parasympathetic control (3) the process of heart failure can 
be reversed through LVAD support, and (4) biofeedback is a tool that can be used to 
teach patients to alter autonomic input to the cardiovascular system.   
We hypothesized that use of biofeedback-assisted stress management 
training to downregulate sympathetic nervous system activity and upregulate 
parasympathetic nervous system activity, will provide a non-invasive 
psychophysiologic means to reverse myocardial remodeling in patients with end-


























If heart rate = 72 beats per minute, then IBI = (60 seconds / 72 bpm) x 1000 
IBI = 833 milliseconds
Figure 5.   Heart rate variability. 
 
Heart rate variability (HRV) is the beat-to-beat fluctuation in heart 
rate, also called the inter-beat interval (IBI).  It has recently joined 
other biofeedback modalities as a direct measure of autonomic balance 
and cardiovascular resilience.  Greater HRV has been associated with 
greater cardiovascular health, and patients with end-stage heart failure 











2.1  Patient Selection 
Patients were enrolled in the experimental group (failing + BF) if they had advanced 
heart failure (New York Heart Association Class III or Class IV) and were listed for 
cardiac transplantation at the Cleveland Clinic.  All patients received standard medical 
therapy for heart failure, including maximally tolerated doses of angiotensin converting 
enzyme inhibitors, angiotensin II receptor blockers, aldosterone antagonists and cardiac 
resynchronization therapy / implantable cardioverter defibrillators if indicated by their 
heart failure cardiologist.  Inpatients were also treated with intravenous inotropic agents.   
Patients who were excluded from the failing + BF group include those who had a 
mechanical assist device at the time of transplant listing or those who required an assist 
device while waiting for transplantation.  Patients were also excluded if they did not 
speak English and required a translator in order to communicate or if they were unable to 
return to the Cleveland Clinic for eight visits.  Patients in the non-failing, failing and 
failing + LVAD groups were gender-, age-, race-, and (in the failing and failing + LVAD 
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groups) heart failure diagnosis-matched with those in the failing + BF group.  
 
2.2 Biofeedback Protocol 
All patients enrolled in the failing + BF group received the biofeedback-assisted 
stress management training, and each patient served as his or her own control.  Patients 
were not randomized because it was unknown whether advanced heart failure patients 
would even be able to do biofeedback.  Inpatients awaiting transplant in the hospital were 
studied in their rooms twice per week for 4 weeks.  Outpatients awaiting transplant at 
home were studied in the Clinical Research Unit at the Cleveland Clinic once per week 
for 8 weeks.  During training, patients were either seated comfortably in a recliner or 
lying supine in their hospital bed. 
The biofeedback protocol was conducted by a biofeedback-certified psychologist in 
the presence of a biofeedback technician.  The role of the technician was to hook the 
patient up to the biofeedback equipment at the beginning of each session and to monitor 
the raw data throughout each session, addressing any noise in the signal, if possible.  
Signal artifact as well as anything unusual that may have occurred during the session was 
noted by the technician.  The technician was also present to confirm that the biofeedback 
therapist was using only biofeedback and stress management techniques with the patients.  
Specifically, it was important to have an independent party confirm that no 
psychotherapy was being conducted during the biofeedback sessions. 
 
Sensors and Screens 
Standard biofeedback equipment from Thought Technology (Montreal, QC) was used 
to monitor physiologic processes.   Physiologic modalities measured included respiration 
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rate, digital peripheral temperature, skin conductance, heart rate, and heart rate variability 
in the time domain.  Figure 6 shows the four sensors that were used to monitor patients’ 
physiology, and a summary of values when a person is relaxed is provided in Table I. 
 
To measure respiration rate, patients were asked to exhale fully, and a strain gauge 
was placed around their waist, just above the belly button with a small amount of tension.  
The strain gauge is sensitive to stretch, and it converts the expansion and contraction of 
the patient’s abdomen into a rise and fall in the signal transmitted to the computer.  The 
software calculates respiration rate from this raw waveform (in breaths per minute). 
Digital peripheral temperature was measured using a thermistor that was taped along 
the palmar side of the patient’s fifth digit using Millipore medical tape.  Changes in 
finger temperature were converted into an electrical current which was transmitted to the 
computer to display changes in the signal (in degrees Fahrenheit - °F). 
To measure the skin’s ability to conduct electricity, or skin conductance, silver-silver 
chloride electrodes embedded into Velcro straps were placed onto the pads of the 
patient’s second and fourth digits.  When in use, a small electrical voltage was applied 
through the electrodes, establishing an electrical current in which the patient serves as a 
resistor, and the real-time variation in conductance (the inverse of resistance) was 
recorded (in microsiemens - µS). 
Lastly, heart rate was measured using a blood volume pulse sensor that was taped to 
the pad of the patient’s third digit.  This sensor uses photoplethysmography to shine 
infrared light through the skin and measure the light that is reflected back to the sensor.  
Because blood reflects red light and absorbs other colors, the amount of light reflected 





Figure 6.   Biofeedback sensors. 
 
Strain gauge (A) used to measure respiration rate; Thermistor (B) used 
to measure finger temperature; Electrodes (C) used to measure skin 
conductance; Blood volume pulse sensor (D) used to measure heart 
rate / heart rate variability. 
 











































Table I.   Physiologic Signals When A Person Is Relaxed 
        
    
RESP DPT SC HR 
        
    
6 breaths per minute ~ 90°F 2µS ~ 60-80 beats per minute 
        
    
RESP = Respiration Rate, DPT = Digital Peripheral Temperature, SC = Skin Conductance, HR = Heart Rate 
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blood volume pulse signal is a relative measure from which heart rate (beats per minute) 
and inter-beat interval (milliseconds) are calculated.  The raw inter-beat interval data 
were used to calculate measures of heart rate variability in the time domain. 
Custom biofeedback screens were created to provide optimal audio and visual 
feedback to the patients in this study.  As shown in Figures 7-10, each patient screen 
focused on a single physiologic modality.  Figure 11 illustrates a screen that was 
customized for the biofeedback therapist and the biofeedback technician to see a real-
time summary of all physiologic modalities at the same time. 
 
Session Outline 
The first and last study visits (visits 1 and 8) consisted of a custom-designed 32-
minute psychophysiologic assessment of stress reactivity.  During this assessment 
patients were guided through three mental stress tasks, separated by five minute periods 
of rest / self-relaxation.  A five-minute self-relaxation was also conducted at the 
beginning of each assessment, prior to the stressors.  Mental stress tasks included the 
Stroop Color Word Test74, Serial Sevens Test102 and a Stressful Event Recall Task103 in 
which patients were asked to talk about how it feels to be waiting for a heart transplant. 
The six biofeedback-assisted stress management training sessions (visits 2-7) were 
each 45 minutes in length and involved basic relaxation training with biofeedback, 
predominantly respiration and temperature feedback.  Although each training session 
began and ended with a 5-minute self-relaxation, the rest of the session consisted of 
individualized stress management exercises to which the patient best responded. 
A schematic outline of all eight biofeedback sessions can be found in Figure 12. 
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Figure 7.   Respiration rate patient training screen.    
 
The target breathing rate for patients was 6 breaths per minute.  Using 
an adaptive pacer ball, patients were paced to breathe at a rate two 
breaths per minute less than their current respiratory rate, which was 
displayed digitally on the screen (in yellow).  A filled line graph of 
respiratory amplitude was also displayed for patients to learn to 

























Figure 8.   Digital peripheral temperature patient training screen.   
 
In addition to a digital display of finger temperature (in yellow), this 
screen also includes a bar graph that is red as temperature rises and 
turns blue as temperature falls.  The lightbulb is connected to the bar 
graph such that a rise in temperature lights up the bulb, and the bulb 


























Figure 9.   Skin conductance patient training screen.    
 
This screen shows a slideshow of relaxing images that cycle as the 
patient lowers their skin conductance.  If skin conductance rises, the 
current photo goes out of focus, and the slideshow does not advance.  



























Figure 10.   Heart rate variability patient training screen.    
 
Patients were not formally trained using this HRV screen, but HRV 
was monitored throughout all sessions.  This screen shows an adaptive 
pacer ball as well as a line graph displaying the overlap between heart 
rate and respiration rate.  Bar graphs of HRV in the frequency domain 
are also displayed, however this screen was only ever casually referred 
to if the green bar was high so that the biofeedback therapist could 


























Figure 11.   Biofeedback therapist / technician screen.    
 
This screen was created so that all physiologic modalities being 
measured could be viewed simultaneously by the biofeedback 























































35 minutes – Individualized Stress 
Management / Biofeedback 
5-minute Self-Relaxation 
Session 1 
Sessions 2 - 7 
Psychophysiologic Assessment 
   
 5-minute Acclimation 
5-minute Self-Relaxation 
1-minute Stroop Color Word Test 
5-minute Rest (#1) 
1-minute Serial Sevens Test 
5-minute Rest (#2) 
5-minute Stressful Event Recall 
5-minute Rest (#3) 
 
Psychophysiologic Assessment 
   
 5-minute Acclimation 
5-minute Self-Relaxation 
1-minute Stroop Color Word Test 
5-minute Rest (#1) 
1-minute Serial Sevens Test 
5-minute Rest (#2) 
5-minute Stressful Event Recall 





All patients were provided with relaxation CDs, handheld thermometers and daily 
record sheets.   Patients were asked to practice at least 20 minutes per day on their own in 
between sessions, recording their daily stress levels and their finger temperature before 
and after relaxation practice.  This home practice encouraged optimal learning of the 
biofeedback skills which were being taught in the training sessions.  Daily record sheets 
(Figure 13) were collected at each visit, and patients were asked about the frequency and 
success of practice, which were also recorded. 
 
Quality of Life Assessment 
In order to assess whether biofeedback-assisted stress management enhanced 
quality of life for patients awaiting heart transplantation, two questionnaires were 
administered prior to the psychophysiologic assessment in the first and last biofeedback 
sessions. These included the RAND Short-Form 36 (SF-36) general health survey79,80,119 
and the heart failure-specific Kansas City Cardiomyopathy Questionnaire (KCCM)47.  
Both were scored according to standard metrics.47,118 
 
Subjective Data 
Patients were also asked several times throughout each biofeedback session to self-
report aloud their heart failure status, level of relaxation and mood, and these responses 
were recorded.  A 5-point Likert scale was used for each question with 1 being the most 
negative response and 5 being the most positive. 
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Figure 13.   Daily record sheet.    
 
Copies of this data sheet were provided to all patients, and they were 
encouraged to practice relaxation skills at home in between sessions, 



























Clinical course was assessed in ambulatory outpatients during the first and last 
biofeedback sessions.  Upon arrival, patients were asked to lay supine for 30 minutes 
before blood was drawn for measurement of plasma norepinephrine.  Following the 
psychophysiologic assessment in these two sessions, a six minute walk test was 
performed for the objective evaluation of functional exercise capacity.3   
 
2.3  Human Heart Tissue Procurement 
Human heart tissue was acquired at the time of cardiac transplantation.  Immediately 
after excision, each heart was obtained from the operating room and placed into chilled 
cardioplegia (concentration in mM: 77.0 NaCl, 20.0 KCl, 10.0 NaHCO3, 14.0 Glucose, 
0.1 CaCl2) for transport to the laboratory.  Non-failing human hearts were obtained 
through LifeBanc of Northeast Ohio from unmatched organ donors in which the heart 
was not suitable for transplantation due to histoincompatibility or a difference in organ 
size.   Failing human hearts, including those who received biofeedback training and those 
supported by an LVAD, were obtained from recipients undergoing heart transplantation 
at the Cleveland Clinic.  Informed consent was acquired prior to tissue procurement in 
accordance with an approved IRB protocol (IRB #2378, C Moravec Principal 
Investigator). 
 
2.4  Cardiac Muscle Function 
All muscle function experiments were performed at the time of transplant.  Explanted 
hearts were brought back to the lab, and fresh left ventricular trabecular muscles were 
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immediately dissected from the endocardial surface of the heart.  Individual muscles were 
placed between two O-rings and hung in a tissue bath filled with Krebs-Henseleit buffer 
(composition in nM: 100 NaCl, 4 potassium chloride (KCL), 1.5 magnesium sulfate 
heptahydrate (MgSO4*7H2O), 20 sodium bicarbonate (NaHCO3), 1.5 sodium phosphate 
(NaH2PO4), 20 sodium acetate, 10 glucose, 0.1 ascorbic acid, 2.5 anhydrous calcium 
chloride, 5 I.U. insulin) maintained at 37°C (Figure 14). 
For the next hour, total muscle tension was monitored and adjusted every 15 minutes 
to ensure that it stayed close to 1.0g.  No stimulus was given during this time.  After the 
muscles stabilized, GRASS stimulators were turned on to provide repeat stimulation 
(10V, 1Hz), and the minimum voltage necessary to elicit muscle contraction (called the 
threshold voltage) was determined.  To determine the threshold voltage, voltage was 
dialed back to 1V and steadily increased by 1 until the muscle began to contract.  Voltage 
was then reduced by 1V (a voltage where the muscle did not contract) and slowly 
increased by 0.2V until the muscle contracted repeatedly (for ~ 30 seconds).   
The stimulator for each muscle was set to a voltage 20% greater than the empirically 
determined threshold voltage, and this voltage was used for the remainder of the 
experiment.  A length-tension curve was then performed to determine the length at which 
each muscle produces its greatest contraction (Lmax).  With each muscle at its Lmax, the 
effect of any experimental manipulation can be compared across muscles.  To find Lmax, 
baseline resting tension (RT) and developed tension (DT) were recorded, and after 1 
minute, each muscle was stretched by 0.1mm.  RT and DT were recorded 1 minute later, 
and the process continued (stretch muscles, wait 1 minute, record RT and DT) until there 






























Tissue bath with 
Krebs-Henseleit Buffer 
maintained at 37°C 
Figure 14.   Muscle bath set-up.    
 
Human left ventricular trabecular muscles are dissected from the 
endocardial surface of the heart and secured between two O-rings.  
Muscles are then hung in an oxygenated tissue bath containing Krebs-
Henseleit buffer which is maintained at 37ºC.   
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reached, muscles stabilized in the tissue baths for 30 minutes, and only muscles with 
developed tension greater than 0.20g were used for the experiment. 
Baseline data were collected for 5 minutes before 1µM isoproterenol (ISO), a 
laboratory analogue of norepinephrine, was added directly to each tissue bath to mimic 
stimulation by the sympathetic nervous system.  After 10 minutes of data collection under 
the influence of ISO, data were saved in the data acquisition software (LabChart 7 Pro), 
and the tissue baths were lowered.  Calipers were used to measure the length of each 
muscle between the O-rings, and then each muscle was carefully cut out as close to the 
O-rings as possible.  Muscles were dried in bibulous paper for exactly 15 minutes and 
immediately weighed.  The cross-sectional area (XSA; in mg/mm) of each muscle was 
calculated by dividing the weight of each muscle by its length. 
Muscle function at baseline (Lmax) as well as the response to isoproterenol was 
analyzed for six contractile parameters including RT, DT, time to peak tension (TPT), 
time to half relaxation (THR), peak rate of tension rise (+dT/dt), and peak rate of tension 
fall (-dT/dt) (Figure 15). 
   
2.5  Sarcolemmal Membrane Isolation and Purification  
In preparation for beta-adrenergic and muscarinic receptor density measurements, 
sarcolemmal membrane fragments were isolated and purified from frozen human heart 
tissue which had been stored at -80°C.  Frozen tissue samples weighing 2.0g ± 0.2g were 
each placed into 20mL of chilled homogenization buffer A (composition: 10mM N-(2-
Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES), 5mM ethylene glycol-
bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 12.5mM magnesium  
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Figure 15.   Individual muscle contraction showing six contractile 
parameters.    
 
Muscle function was evaluated with respect to six contractile 
parameters.  Resting tension (RT) is the tension produced by the 
muscle at rest.  Developed tension (DT) is the force produced by the 
muscle during contraction.  Time to peak tension (TPT) is the time it 
takes for the muscle to reach the peak of its contraction.  Time to half 
relaxation (THR) is the time it takes for the muscle to get from that 
point of peak contraction to halfway through its relaxation.  Peak rate 
of tension rise (+dT/dt) is the maximal rate of contraction (represented 
by the steepest point of the line leading to the peak of the muscle 
contraction).  Peak rate of tension fall (-dT/dt) is the maximal rate of 
relaxation and is represented by the steepest point of the relaxation 


































chloride (MgCl2), 250mM sucrose, 20µg/mL leupeptin, 20µg/mL phenylmethylsulfonyl 
fluoride (PMSF), 20µg/mL bacitracin, 20µg/mL benzamidine) and homogenized using a 
Polytron homogenizer until there was little foam and no visible chunks of tissue floating 
in the homogenate.  In order to minimize heat production and thereby the potential 
destruction of proteins, homogenization was carried out on ice in 3-second bursts with 5 
seconds of rest in between activity to allow the homogenization probe to cool. 
Homogenates were centrifuged at 4°C and 300 x g for 5 minutes so that heavier 
organelles such as nuclei and mitochondria precipitated out.  Avoiding the pellet and 
layer of fat, supernatants were recovered and incubated in 0.5M KCl at 4°C for 15 
minutes to remove myofilaments.  These suspensions were centrifuged at 4°C and 40,000 
x g for 15 minutes in order to pellet the membrane fraction.  Supernatants were discarded, 
and pellets were added to chilled homogenization buffer B (composition: 20mM HEPES, 
5mM EGTA, 12.5mM MgCl2, 100mM sodium chloride (NaCl), 10µg/mL leupeptin, 
20µg/mL PMSF, 20µg/mL bacitracin, 20µg/mL benzamidine).   
Pellets were dounce homogenized in buffer B on ice, 10 times with a loose-fitting 
pestle and 10 times with a tight-fitting pestle, in order to purify the membrane fraction.  
Preparations were centrifuged at 4°C and 40,000 x g for 15 minutes, and pellets were 
recovered and dounce homogenized a second time (in buffer B, on ice, 10 times with a 
loose-fitting pestle and 10 times with a tight-fitting pestle) before a final centrifugation to 
refine the membrane preparation (again at 4°C and 40,000 x g for 15 minutes).  Pellets 
were resuspended in buffer B + 10% glycerol (preserves the membrane preparations 
throughout storage) and completely solubilized using a motorized dounce homogenizer.  
Aliquots were stored at -80°C. 
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2.6  Measurement of Total Protein for Receptor Density Analysis 
Total protein concentration was determined by the Lowry method using Bio-Rad 
reagents.  Standards containing known concentrations (0, 500, 1000, 2000, 3000 and 
4000 µg/mL) of bovine serum albumin (BSA) were pipetted into a 96-well microtiter 
plate in triplicate.  Membrane preparations were diluted 1:2 in deionized water (dH2O) 
and also added to the microtiter plate in triplicate.  Reagent A, an alkaline copper tartrate 
solution, was added to each standard and sample to bind to the peptide bonds in all 
proteins.  A dilute folin reagent, Reagent B was then added to each standard and sample 
to recognize Reagent A and to produce a characteristic blue color directly proportional to 
the amount of protein in the sample.  After a 15-minute incubation at room temperature, 
absorbance was read at 750nm.  Using the absorbance values for the known 
concentrations of BSA to generate a standard curve, the total protein concentration for 
each unknown sample was determined by interpolation.  
 
2.7  Total Beta-Adrenergic Receptor Density 
Beta-adrenergic receptor density was measured by radioligand binding analysis.  In 
order to optimize conditions for radioligand binding, membrane titer assays were run.  
Specifically, six polypropylene tubes were arranged on ice for each membrane fraction to 
be measured.  The assays were run in triplicate with three tubes used to measure total 
binding and three tubes to measure non-specific binding.  A reaction buffer (HEM) 
(composition in mM: 20 4-(2-hydroxyethyl)-1-piperaineethanesulfonic acid (HEPES), 15 
EGTA, 1.25 MgCl2) plus 0.1% BSA was added to all six tubes for each sample.  
Propranolol (10-5M), an unlabeled non-selective beta-adrenergic receptor blocker, was 
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then added to each non-specific binding tube.  Next, a non-selective radiolabeled 
antagonist, 125I-Cyanopindolol (ICYP) (30pM), was added to all reaction tubes.  Finally, 
each membrane fraction was prepared in HEM + BSA buffer to a final protein 
concentration of 25µg/µL and added to all reaction tubes.  All tubes were mixed and 
incubated in a shaking water bath at 37°C and 65 RPM for one hour.  Following 
incubation, contents of each reaction tube were trapped onto glass fiber filter paper using 
a cell harvester.  Forceps were used to carve out an individual filter for each reaction 
tube, and each filter was placed into a new polypropylene tube.  The new polypropylene 
tubes were taken to a gamma radiation counter where the amount of radioactivity trapped 
on each piece of filter paper was determined.  Each tube was read for one minute, and 125I 
was measured in counts per minute.  Triplicate values were averaged, and average non-
specific binding was subtracted from average total binding to obtain a specific binding 
value for each sample.  Because our laboratory has previously determined that the 
optimal running condition for radioligand binding assays is at 10% of the dissociation 
constant (Kd)92, the amount of membrane necessary to run under this condition was 
calculated for each sample. 
Next the radioligand binding assay was performed using seven doses of ICYP in the 
presence of 10-5M propranolol.  Similar to the membrane titer assay, everything was run 
in triplicate, with three tubes for measuring total binding and three tubes for measuring 
non-specific binding for each dose of ICYP for each sample (42 tubes / sample).  The 
experiment was run with all tubes on ice.  The highest concentration of ICYP (250pM) 
was prepared in HEM + BSA buffer, and subsequent doses were achieved via serial 
dilution (in pM: 125, 63, 31, 16, 8, 4).  HEM + BSA buffer and propranolol were added 
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as described in the membrane titer assay.  Each ICYP dose was added to six tubes (three 
total binding and three non-specific binding) for each sample, from the lowest 
concentration to the highest.  Membrane preparations were prepared in HEM + BSA 
buffer according to the calculations from the membrane titer assay (at 10% Kd) and added 
to all 42 tubes for each sample.  All tubes were mixed, incubated, harvested, and 
radioactivity was quantified again using the same procedure as in the membrane titer 
assay.  In order to determine total density and Kd for each sample, Scatchard analyses 
were performed.  Figure 16 shows a typical saturation curve and Lineweaver-Burk plot 
generated in the Scatchard analysis.   
 
2.8  Total Muscarinic Receptor Density 
Much like the measurement of beta-adrenergic receptor density, total muscarinic 
receptor density was measured by radioligand binding assay, preceded by membrane titer 
analysis in order to optimize conditions.  The membrane titer assay protocol was the 
same as that outlined in section 2.8, except that 1µM atropine was used as the unlabeled 
non-selective muscarinic receptor blocker, and 250pM 3H-Quinuclidinyl benzilate (QNB) 
served as the non-selective radiolabeled antagonist.  Also, following the cell harvesting 
step, individually carved filters were placed into scintillation vials and incubated in a 
hybridization oven at 42°C until dry (~5 minutes).  All scintillation vials were then filled 
with Cytoscint scintillation fluid, mixed and wiped with a dryer sheet to prevent 
artificially high radiation readings from static.  Before vials were read, they sat overnight 
on the benchtop at room temperature.  The next day, all vials were taken to the 
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Figure 16.   Typical saturation curve and Lineweaver-Burke plot.   
 
Scatchard analyses generate a saturation curve and a Lineweaver-Burk 
plot.  The saturation curve (top) illustrates the relationship between the 
concentration of radioactivity used and the amount of binding.  The 
Lineweaver-Burk plot (bottom) illustrates the relationship between the 
amount of specific binding and the ratio of bound to free radioactivity.  
The x-intercept represents the density (Bmax) of the measured 
receptor, and the slope represents the binding affinity (Kd). 
 

























measured in counts per minute, and specific binding values were obtained by subtracting 
average non-specific binding from average total binding.  This protocol was recently 
worked out in our laboratory, and it was determined that the optimal running condition 
for radioligand binding assays aimed at measuring muscarinic receptors is at 10% of the 
Kd (unpublished).  The amount of membrane necessary to run under this condition was 
calculated for each sample. 
To measure total muscarinic receptor density via radioligand binding, the same 
general process described in section 2.8 was employed.  In this case, eight doses of 3H-
QNB were used in the presence of 1µM atropine.  The highest dose of QNB was 
1500pM, and non-logarithmic serial dilutions were used to prepare the remaining seven 
doses (in pM: 900, 540, 270, 135, 68, 27, 11).  The cell harvesting steps were the same as 
those described above, and again, Scatchard analyses were performed to obtain final total 
binding and Kd values for each sample. 
 
2.9  Tissue Homogenization for Western Blotting 
Homogenization was done on ice in a Tris-EDTA (ethylenediaminetetraacetic acid) 
radioimmunoprecipitation assay (RIPA) buffer (composition: 20mM Tris, pH 7.4; 
100mM NaCl; 5mM EDTA, pH 8.0; 10% glycerol; 50mM sodium fluoride (NaF); 1% 
Triton X-100; 0.1% sodium dodecyl sulfate (SDS); 1% sodium deoxycholate (DOC); 
1mM sodium pyrophosphate (Na4P2O7); 1mM sodium orthovanadate (Na3VO4); 
10µg/mL PMSF) which also contained a standard cocktail of protease inhibitors for 
mammalian tissues (Sigma).  All protease / phosphatase inhibitors were added just before 
use.  Homogenization of human heart tissue samples (~ 300mg each) was performed on 
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ice using a Polytron homogenizer 3 times for 3 seconds each with 5-second rests between 
each homogenization.  Homogenates were centrifuged at 4°C and 2,000 RPM for 10 
minutes.  Supernatants were recovered, and aliquots were stored at -80°C. 
 
2.10  Measurement of Total Protein for Western Blotting 
Total protein concentration was determined by the Lowry method using the Bio-Rad 
DC (detergent-compatible) protein assay kit.  The process was the same as the protein 
assay used prior to receptor density measurements, except for the following: standard 
concentrations were 0, 200, 400, 600, 800 and 1,000 µg/mL BSA; homogenates were 
diluted 1:50; and Reagent S, a surfactant solution was added to Reagent A before it was 
added to the microtiter plate.  
 
2.11  Western Blotting to Measure Calcium-Cycling Proteins 
Homogenates were diluted in Laemmli buffer containing β-2-mercaptoethanol to a 
concentration of 4µg/µL.  Proteins were separated on 8.0% (SERCA) or 7.0% (CALQ) 
SDS-PAGE running gels with 4% stacking gels.  In the case of RYR, a 4-20% precast 
linear gradient gel (Bio-Rad) was used for protein separation.  Gels were run at 125V in 
chilled running buffer (composition in mM: 19 tris(hydroxymethyl)aminomethane (Tris), 
3.5 SDS, 192 glycine) until the dye front reached the bottom of gel (~90 minutes).  
Because RYR is such a large, globular protein, it was run at 125V for 2.5 hours on ice to 
avoid overheating. 
Proteins were electroblotted onto polyvinylidene fluoride (PVDF) membranes in ice-
cold transfer buffer (composition in mM: 17 Tris, 181glycine, 20% methanol (MeOH)) 
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on ice at 100V for 2 hours (3 hours for RYR gels).  Blots were blocked with 5% milk in 
tris buffered saline (TBS)-Tween for 2 hours and incubated in primary antibody at 4°C 
overnight on a rotisserie.  The next day, blots were washed with TBS-Tween 4 times for 
5 minutes each and incubated (shaking) in secondary antibody at room temperature for 1 
hour.  Exact antibody conditions can be found in Table II.  
Blots were washed again with TBS-Tween 4 times for 5 minutes each.  Blots were 
then developed via chemifluorescence using the Odyssey infrared scanner (Li-Cor, NE) 
and quantified with Odyssey version 3.0 software.  Each sample was normalized to a 
non-failing sample that was run on every gel, which allowed for comparisons across gels. 
 
2.12  Data Analysis 
Biofeedback, Quality of Life and Clinical Data 
 For all before and after biofeedback training analyses, paired t-tests were 
performed.  If the data were not normally distributed, then a Wilcoxon matched-pairs 
signed rank test was used to make comparisons. 
 Across-session analyses were performed using a one-way repeated measures 
analysis of variance (ANOVA) with Newman-Keuls post-hoc testing when necessary.  
Freidman tests with Dunn’s Multiple Comparison post-hoc tests were performed when 
the data did not follow a normal distribution. 
 Inpatient versus outpatient comparisons were made using a 2-way repeated 
measures ANOVA and Bonferroni post-hoc analyses. 
In all cases, alpha was set at 0.05, and analyses were performed using GraphPad 







    
Host Primary Antibody 1° Ab Dilution 2° Ab Dilution 
    
    
Mouse Anti-SERCA 1:30K 1:20K 
Rabbit Anti-NCX 1:10K 1:10K 
Mouse Anti-RYR 1:3K 1:10K 
Rabbit Anti-CALQ 1:10K 1:20K 















Table II.   Western Blot Antibody Conditions
SERCA, RYR and CALQ primary antibodies were from Thermo Scientific (Golden, CO).  NCX 
primary antibody was from Swant (Switzerland).  All secondary antibodies were from Li-Cor 
Biosciences (Lincoln, NE). 
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Removing Artifact from Heart Rate Variability Data 
 Before comparisons were made with respect to heart rate variability, the raw data 
had to be analyzed for potential artifacts.  Artifacts were defined as inter-beat intervals 
that did not match up with a pulse on the blood volume pulse trace.  Raw inter-beat 
interval data were scrolled through, and the cursor on the blood volume pulse trace 
“jumped” from pulse to pulse.  When the cursor did not land on a pulse, then this was 
considered to be an artifact, and it was manually removed using one of three strategies: 
(1) if the IBI value was longer than those nearby, then it was split into two equal IBI 
values, (2) if the IBI value was longer than those nearby and the consecutive IBI was 
shorter than those nearby (or vice versa; if the two consecutive IBIs were a relatively 
short value followed by a relatively long value), then the two consecutive IBIs were 
averaged, and (3) if there were two consecutive short IBI values, then the IBIs were 
added.  All heart rate variability artifact removal was performed using CardioPro Infiniti: 




A one-way ANOVA was used to compare non-failing, failing, failing + LVAD and 
failing + BF groups with respect to muscle function, total receptor density and Kd (beta-
adrenergic and muscarinic), as well as the relative presence of calcium-cycling proteins.  
When necessary, Newman-Keuls post-hoc tests were performed.  If any one of the groups 
did not follow a normal distribution, as determined by the Kolmogorov-Smirnov test, 
then a Kruskal-Wallis test was performed with Dunn’s Multiple Comparison post-hoc 
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analysis.  Alpha was set at 0.05, and analyses were performed using GraphPad Prism 
software, version 5.02 (San Diego, CA). 
 
Correlation Data 
To determine whether success with biofeedback was related to biological change, 
linear regressions were performed.  The correlations were analyzed using GraphPad 









































3.1 Biofeedback Data 
Table III shows demographic data on the 35 patients enrolled in the biofeedback 
portion of this study.  Highlighted in gray are the 20 patients who completed the entire 
biofeedback-assisted stress management training protocol (all eight sessions of 
biofeedback), and only these 20 patients were used in the biofeedback data analysis.  
Summary demographics on these 20 patients can be found in Table IV.   
 
Respiration Rate 
The first physiologic modality focused on during biofeedback-assisted stress 
management training was respiration.  Figure 17 shows that patients were able to lower 
their average respiration rate from 14.9 ± 2.9 breaths per minute in session 1 (before 
biofeedback training) to 9.4 ± 2.7 breaths per minute in session 8 (after biofeedback 
training) (p < 0.001).  In order to determine how many training sessions it took before a 







 Age Sex Race Diagnosis LVEF (%) Medications 
IP 1 59 M W ICM 15 ACE I, BB 
IP 2 66 M W ICM 10 AAR, BB, DIG 
IP 3 61 M W ICM 20 ACE I, BB, DIG 
IP 4 53 F B DCM 15 ACE I, BB 
IP 5 61 F W DCM 10 ACE I, BB, DIG 
IP 6 58 M W DCM 30 ACE I, BB 
IP 7 27 M W CONG 10 N/A 
IP 8 46 M W Restrictive CM 60 N/A 
IP 9 52 F W DCM 15 AAR, ACE I, BB, DIG 
IP 10 45 M W CONG 55 BB, DIG 
IP 11 65 M W DCM 15 ARB, BB, DIG 
IP 12 63 F W ICM 20 ACE I, BB, DIG 
IP 13 28 F B DCM 20 INO 
IP 14 69 M W ICM 15 AAR, ACE I, BB, DIG, INO 
IP 15 61 M B DCM 10 BB, INO 
IP 16 68 M W ICM 51 AAR, BB, DIG, INO 
IP 17 50 M B DCM 20 AAR, BB, DIG 
IP 18 61 M W Amyloidosis 20 N/A 
IP 19 55 F W HCM 10 AAR, BB 
IP 20 66 M W DCM 30 ACE I, BB 
IP 21 58 M W DCM 37 AAR, BB 
OP 1 59 M W DCM 20 ACE I, BB, DIG 
OP 2 20 M H DCM 18 ACE I, BB, DIG 
OP 3 60 F W DCM 25 Not Listed for Transplant 
OP 4 52 M W DCM 15 ACE I, BB 
OP 5 67 F B DCM 10 AAR, ACE I, BB, DIG, OVD 
OP 6 43 M B ICM 12 ACE I, BB 
OP 7 44 M W CONG 15 ACE I, BB, DIG 
OP 8 61 M W ICM 20 ACE I, DIG 
OP 9 49 M W ICM 20 BB 
OP 10 20 M W Restrictive CM 30 ACE I, BB 
OP 11 46 F B DCM 10 BB 
OP 12 64 M W DCM 30 ACE I, BB, DIG 
OP 13 66 M W DCM 10 AAR, ACE I, BB 
OP 14 61 M W ICM 19 BB, OVD 
Table III.   Demographics of the 35 End-Stage Heart Failure Patients Enrolled in the Study 
IP = inpatient; OP = outpatient; M = male; F = female; W = white; B = black; H = Hispanic; DCM = dilated 
cardiomyopathy; ICM = ischemic cardiomyopathy; HCM = hypertrophic cardiomyopathy; CONG = congenital; AAR = 
anti-arrhythmic; ACE I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BB = beta 
blocker; DIG = digoxin; INO = inotrope; OVD = other vasodilator 


























Patient Status (n = 20)
     Inpatient 







56 ± 10 
 
Gender 
     Male 







     White 







     III 







     DCM 
     ICM 
     CONG 
     Restrictive CM 











23 ± 15 
 
Medications 
     AAR 
     ACE I 
     ARB 
     BB 
     DIG 









Table IV.   Demographics of the 20 End-Stage Heart Failure Patients 
Who Completed All 8 Sessions of Biofeedback 
DCM = dilated cardiomyopathy; ICM = ischemic cardiomyopathy; CONG = congenital; AAR 
= anti-arrhythmic; ACE I = angiotensin converting enzyme inhibitor; ARB = angiotensin 












































Figure 17.   Average respiration rate during self-relaxation before 
and after biofeedback training.    
 
Patients lowered their respiration rate from 14.9 ± 2.9 breaths per 
minute before biofeedback training to 9.4 ± 2.7 breaths per minute 
after biofeedback training (p < 0.001).   
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After only three sessions of biofeedback training (session 4), patients were breathing at a 
significantly lower rate than they were in session 1 before they had any formal training (p 
< 0.05), and respiratory rate continued to decrease throughout the remaining sessions 
(Figure 18). 
Respiration rate was also evaluated as the percentage of time patients spent 
meeting specific criteria before and after biofeedback training.  Self-relaxation portions 
of the psychophysiologic assessment, including the 5-minute self-relaxation at the 
beginning of the session and the rest periods (each five minutes in length) following each 
mental stress task, were aggregated and labeled as “relaxation time.”  As shown in 
Figure 19, patients spent a significantly greater percentage of relaxation time breathing at 
rates at or less than 10 (p < 0.001), 8 (p < 0.001) and 6 (p < 0.01) breaths per minute after 
biofeedback training. 
Clinical significance was also analyzed by assigning a letter grade to each 
patient’s average breathing rate during the 5-minute self-relaxation of the 
psychophysiologic assessment before and after biofeedback training.  Table V illustrates 
that 80% of patients made clinical improvements in their respiration rate from session 
one to session eight.  
 
Inpatients vs. Outpatients 
Respiration rate data were also analyzed by patient status (inpatients vs. 
outpatients).  As shown in Figure 20, there were no significant differences between these 
groups (p = 0.86), but both inpatients and outpatients significantly lowered their 
















































Figure 18.   Average respiration rate during self-relaxation across 
all biofeedback sessions.    
 
Average respiration rate among patients decreased across sessions, 
reaching a significantly lower rate (relative to session 1) in session 4 
(p < 0.05) and continued to decrease in session 5 (p < 0.01) and 



















































Figure 19.   Percentage of relaxation time patients spent breathing 
at lower rates before and after biofeedback training.    
 
Patients spent significantly more time breathing at or less than 10, 8 
and 6 breaths per minute, following biofeedback training (     p < 0.01 










Change in Clinical Rank Number (%) of Patients 
    
  
D → A 6 (30) 
D → B 4 (20) 
C → A 2 (10) 
C → B 2 (10) 
B → A 2 (10) 
No Change 4 (20) 
















KEY:  A = 9 or lower; B = 10-12; C = 13-15; D = 16 or greater breaths per minute 
 

































Figure 20.   Average respiration rate during self-relaxation before 
and after biofeedback training in inpatients and outpatients. 
 
No significant differences between inpatients and outpatients were 
found, but both groups significantly lowered their respiration rate 
following biofeedback training (inpatients: p < 0.001 vs. Before 
Training; outpatients: p < 0.01 vs. Before Training).   
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per minute in session 1 to 9.4 ± 2.6 breaths per minute in session 8 (p < 0.001), and 
outpatients went from 14.4 ± 1.8 breaths per minute in session 1 to 9.5 ± 3.0 breaths per 
minute in session 8 (p < 0.01). 
In the across-sessions analysis, inpatients were able to significantly lower their 
respiration rate earlier in biofeedback training than outpatients.  As shown in Figure 21, 
inpatient breathing rate reached statistical significance by session 4 (p < 0.05), and 
outpatients were breathing at a significantly lower rate in session 6 (p < 0.05). 
No differences between inpatients and outpatients were found in the percentage of 
relaxation time patients met specific criteria (percent counter) analysis.  In all cases, both 
inpatients and outpatients spent significantly more relaxation time breathing at lower 
rates after biofeedback training (p-values vs. before training are shown in Table VI).  
 
Digital Peripheral Temperature 
In addition to respiration rate, digital peripheral temperature was also analyzed 
before and after biofeedback training as well as across all biofeedback sessions.  Figure 
22 shows that there were no significant changes in finger temperature following 
biofeedback training (p = 0.72) or across biofeedback sessions (overall p-value = 0.99).  
Two patients were able to make a clinically significant improvement in finger 
temperature, moving from a range of 80-90°F in session 1 to ≥ 90°F in session 8. 
 
Inpatients vs. Outpatients 
No significant differences in temperature were found between inpatients and 


























Figure 21.   Average respiration rate during self-relaxation across 
all biofeedback sessions in inpatients and outpatients.   
 
With respect to session 1, inpatients (A) were able to lower respiration 
significantly in session 4 (p < 0.05), and outpatients (B) significantly 
lowered respiration rate in session 6 (p < 0.05).  




























































      
≤ 10 breaths per minute ≤ 8 breaths per minute ≤ 6 breaths per minute 
      
IPs OPs IPs OPs IPs OPs 
      
      
p < 0.001 p < 0.01 p < 0.01 p < 0.01 p < 0.05 p < 0.05 
















Table VI.   Respiration Rate Percent Counter Summary for Inpatients and 
Outpatients 
The p-values shown are vs. before training. 
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Figure 22.   Average finger temperature following and throughout 
biofeedback training.    
 
Digital peripheral temperature did not change significantly (A) 
following biofeedback training (p = 0.72) or (B) across biofeedback 
sessions (p = 0.99).  









































































p = 0.63; OP: p = 0.94).  Of the two patients who made clinical improvements in their 
finger temperature, one was an inpatient, and one was an outpatient. 
 
Skin Conductance 
Due to safety precautions, skin conductance sensors were not used in patients who 
had a pacemaker.  As a result, skin conductance was only able to be measured in two 
patients (both inpatients), and therefore it was analyzed across biofeedback sessions only.  
No significant changes were made in skin conductance throughout biofeedback sessions 
(p = 0.39) as shown in Figure 23, but the average skin conductance value at each session 
was below 2µS, a value that represents relaxed physiology. 
 
Heart Rate Variability 
The standard deviation of the inter-beat interval (SDNN) during the 5-minute self-
relaxation of each session was calculated and compared before and after biofeedback 
training as well as across all biofeedback sessions.  Figure 24 shows that average SDNN 
increased significantly after biofeedback training (p < 0.05), from 32 ± 22 milliseconds to 
44 ± 23 milliseconds.  On an individual basis, 5 out of 20 patients (25%) increased their 
SDNN from an unhealthy range (0-50 msec) to a moderately healthy range (50-100 
msec), as defined by the Task Force of the European Society of Cardiology and the North 
American Society of Pacing Electrophysiology.110 
When analyzing SDNN across all biofeedback sessions, 5 patients were dropped 
from the analysis because there was missing data in one of their eight sessions, and 


































Figure 23.   Average skin conductance during self-relaxation 
across all biofeedback sessions.    
 
Skin conductance (n = 2) did not change significantly across 































Figure 24.   Average SDNN during self-relaxation before and after 
biofeedback training.    
 
On average, patients’ SDNN increased from 32 ± 22 msec to 44 ± 23 
msec following biofeedback training (p < 0.05 vs. Before Training).  
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variance.  The across-sessions analysis of the 15 remaining patients for which all data 
were present showed that SDNN increased significantly across sessions (overall p-value 
= 0.03), as shown in Figure 25.   
SDNN data were also analyzed across sessions using all 20 patients (1) by 
replacing missing values with the same value as the previous session and (2) by replacing 
missing values with an average of the values from the session before and after the 
missing session, but neither of these analyses showed a significant change over time ((1) 
p = 0.09; (2) p = 0.37). 
 
Inpatients vs. Outpatients 
When the SDNN data (n = 15) was separated by patient status, no significant 
differences were found before and after biofeedback training (p = 0.69).  Although not 
significant, outpatient SDNN before training (24 ± 18 msec) was lower than inpatient 
SDNN before training (37 ± 24 msec) (Figure 26).  Across biofeedback sessions, 
outpatients showed a significant increase in SDNN (overall p-value = 0.01) that was not 
present in the inpatient sample (p = 0.62) (Figure 27). 
 
Psychophysiologic Reactivity and Recovery 
 In order to assess the effects of biofeedback-assisted stress management training 
on patients’ response to mental stress, instantaneous heart rate was analyzed before, 
during and after each mental stress task in the psychophysiologic assessment before and 
after biofeedback training.  Figure 28 shows that there was no significant difference in 






























Figure 25.   Average SDNN during self-relaxation across all 
biofeedback sessions.    
 
SDNN (n = 15) increased significantly across sessions (overall p-value 































Figure 26.   Average SDNN during self-relaxation before and after 
biofeedback training in inpatients and outpatients. 
 
Outpatient (n = 7) SDNN before training, while not significant (p = 


























Figure 27.   Average SDNN during self-relaxation across all 
biofeedback sessions in inpatients and outpatients.   
 
(A) Inpatients (n = 8) did not change SDNN across biofeedback 
sessions (p = 0.62).  (B) Outpatients (n = 7) significantly increased 
SDNN across biofeedback sessions (p = 0.01).  
B 
































































Figure 28.   Average heart rate during five-minute baseline in 
psychophysiologic assessment before and after biofeedback 
training.    
 
Baseline heart rate was not significantly different in the 
psychophysiologic assessment before and after biofeedback training (p 
= 0.45). 
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Cardiovascular reactivity to each stressor was measured by subtracting the 
average heart rate before the stressor from the average heart rate during the stressor, and 
both absolute change and percent change were analyzed.  Following biofeedback 
training, cardiovascular reactivity (absolute change) decreased in response to the Stroop 
Color Word Test (5.5 ± 8.5 to 3.8 ± 7.3 beats per minute) and increased in response to the 
Serial Sevens (2.5 ± 8.4 to 3.5 ± 7.6 beats per minute) and Stressful Event Recall (4.9 ± 
8.8 to 8.4 ± 6.8 beats per minute) tasks, however none of these changes reached statistical 
significance (p = 0.34, 0.87, and 0.16, respectively). 
 Using this same method of calculating absolute change in cardiovascular 
reactivity, trends were established for each stressor, and the results are summarized in 
Table VII.  Overall, not counting the patients whose reactivity did not change, about half 
the remaining patients reacted less to mental stress following biofeedback training, and 
about half the patients reacted more. 
The most reliable measure of cardiovascular reactivity is an aggregate percent 
change score calculated by adding the percent change response for all three stressors and 
comparing this value before and after biofeedback training.70  Figure 29 shows that 
overall, cardiovascular reactivity did not change after biofeedback training (p = 0.86). 
Recovery from mental stress was also evaluated by subtracting the average heart 
rate before each stressor from the average heart rate after the stressor.  Absolute and 
percent change scores were calculated, with positive values indicating that the baseline 
heart rate had not been reached (average heart rate after the stressor still higher than the 
average heart rate before the stressor), and negative scores indicating that the baseline 

































        
    
Stroop 9 4 7 
Math 6 4 10 
Recall 9 2 9 
        
    
 24 / 60 (40%) 10 / 60 (17%) 26 / 60 (43%) 
        







































Figure 29.   Overall cardiovascular reactivity to mental stress 
following biofeedback training.    
 
There was no significant change in cardiovascular reactivity to mental 
stress following biofeedback training (p = 0.86).  Data are expressed 
as an aggregate percent change. 
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the average heart rate before the stressor). 
Following biofeedback training, patients recovered less from the Stroop Color 
Word Test (0.23 ± 3.7 to 1.8 ± 5.0 beats per minute) and more from the Serial Sevens (-
0.41 ± 4.3 to -1.8 ± 6.3 beats per minute) and Emotional Event Recall (-5.6 ± 7.1 to -8.1 
± 7.3 beats per minute) stressors, however none of these changes were significant (p = 
0.39, 0.78, and 0.30, respectively).  The percent change aggregate recovery data 
(calculated by adding the percent change response for all recoveries), shown in Figure 
30, also indicates that there was no significant change in cardiovascular recovery from 
mental stress following biofeedback training (p = 0.28). 
 
Inpatients vs. Outpatients 
 When the data were separated into inpatients and outpatients, no significant 
differences were found in average baseline heart rate prior to mental stress before or after 
biofeedback training (p = 0.97).   
Figure 31 shows the aggregate percent change scores for cardiovascular reactivity 
and recovery separated by patient status.  Although not significant (p = 0.24), inpatients 
reacted more to mental stress following biofeedback training, and outpatients reacted 
less.  With respect to cardiovascular recovery, overall results were significant (p = 0.01); 
inpatients recovered from mental stress more than outpatients. 
 
3.2  Homework Data 
Table VIII shows the number of homework sheets that were turned in by each 


















































Figure 30.   Overall cardiovascular recovery from mental stress 
following biofeedback training.    
 
There was no significant change in cardiovascular recovery from 
mental stress following biofeedback training (p = 0.28).  Data are 




















































Figure 31.   Overall cardiovascular reactivity and recovery before 
and after biofeedback training in inpatients and outpatients.    
 
Cardiovascular reactivity to mental stress (A) increased in inpatients 
and decreased in outpatients following biofeedback training, although 
the differences were not statistically significant.  Cardiovascular 
recovery from mental stress (B) was significantly greater in inpatients 































         
IP 2 2 OP 4 - IP 1 5 IP 17 0 
IP 5 4 OP 5 2 IP 3 23 IP 18 5 
IP 6 0 OP 6 - IP 4 3 OP 1 34 
IP 9 0 OP 10 0 IP 7 0 OP 3 34 
IP 12 0 OP 14 0 IP 8 12 OP 7 28 
IP 13 0    IP 10 0 OP 8 17 
IP 19 0    IP 11 0 OP 9 34 
IP 20 6    IP 14 6 OP 11 16 
IP 21 9    IP 15 0 OP 12 4 
OP 2 0    IP 16 0 OP 13 12 

















Table VIII.   Number of Homework Sheets Turned In
Patients highlighted in bold type are the 20 patients who completed all 8 sessions of biofeedback 
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of biofeedback. 
The 20 patients who completed all eight sessions of biofeedback were put into 
quartiles based on the number of homework sheets they turned in, and as shown in 
Figure 32, outpatients did more homework than inpatients.  This result reached statistical 
significance when the average number of homework sheets turned in was compared.  
Inpatients turned in 5 ± 7 sheets, and outpatients turned in 22 ± 12 sheets (p < 0.01). 
 
3.3  Quality of Life Data 
SF-36 
 Table IX lists the mean of each SF-36 aggregate score before and after 
biofeedback training and its corresponding p value.  Note that aggregate scores are out of 
100, and an increase in score reflects a greater level of functioning.  No significant 
differences were found. 
 
Inpatients vs. Outpatients 
Each aggregate score was also separated by patient status, and eight out of ten 
scores did not show any significant differences.  As shown in Figures 33 and 34 
respectively, inpatients had a lower social functioning score (p < 0.05) and a greater 
general health score (p < 0.05) when compared to outpatients. 
The eight aggregate scores for which clinically important differences have been 
established123 are shown in Table X.  For both inpatients and outpatients, some changes 












Quartile 1  =  0 sheets turned in
Quartile 2  =  1 - 5 sheets turned in
Quartile 3  =  6 - 20 sheets turned in
























Figure 32.   Quartile distribution of homework turned in by 
inpatients and outpatients.    
 
Outpatients turned in more homework than inpatients.  This difference 
was statistically significant when the average number of homework 
sheets turned in was compared.  On average, inpatients turned in 5 ± 7 





    
 Before After  
Aggregate Score Biofeedback Training Biofeedback Training p - value
        
    
Physical Functioning 29.5 ± 22.4 30.5 ± 22.35 0.72 
Role Limitations (Physical) 10.5 ± 25.4 11.8 ± 21.0 0.71 
Role Limitations (Emotional) 45.0 ± 43.6 38.3 ± 43.6 0.35 
Energy / Fatigue 34.4 ± 19.8 40.1 ± 25.0 0.17 
Emotional Well-Being 67.5 ± 20.0 68.8 ± 18.1 0.76 
Social Functioning 48.2 ± 31.5 50.8 ± 30.7 0.20 
Pain 58.5 ± 25.6 65.6 ± 24.0 0.22 
General Health 34.4 ± 19.3 35.8 ± 21.4 0.45 
PHYSICAL SUMMARY 28.2 ± 5.89 29.8 ± 7.59 0.23 
MENTAL SUMMARY 46.1 ± 10.8 46.1 ± 10.8 0.97 













Table IX.   Aggregate Scores on SF-36 Before and After Biofeedback Training 










































Figure 33.   SF-36 social functioning aggregate score before and 
after biofeedback training in inpatients and outpatients. 
 
Inpatients reported lower social functioning than outpatients (p < 








































Figure 34.   SF-36 general health aggregate score before and after 
biofeedback training in inpatients and outpatients. 
 
Inpatients reported greater general health relative to outpatients (p < 






         
SF-36 
Summary Score PF RLP RLE EF EWB SF P GH 
                  
         
Minimal 
Clinical Improvement 1 IP 
1 IP 










Clinical Improvement   1 IP 1 IP 
1 IP 
1 OP  2 IP 1 IP 
Large  
Clinical Improvement 1 IP 2 IP       
                  
         
Minimal 














Clinical Decline   
1 IP 
1 OP   1 IP   











Table X.   Clinical Analysis of SF-36 Aggregate Scores 
PF = Physical Functioning, RLP = Role Limitations (Physical), RLE = Role Limitations (Emotional), EF = Energy / Fatigue, 
EWB = Emotional Well-Being, SF = Social Functioning, P = Pain, GH = General Health, IP = Inpatient, OP = Outpatient 
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Kansas City Cardiomyopathy Questionnaire 
Table XI lists the mean of each Kansas City Cardiomyopathy (KCCM) aggregate 
score before and after biofeedback training and its corresponding p-value.  Once again 
the aggregate scores are out of 100, and an increase in score reflects a greater level of 
functioning.  Note that no significant differences were found. 
 
Inpatients vs. Outpatients 
 KCCM aggregate scores were also separated by patient status, and eight out of ten 
summary scores did not show any significant differences.  Figures 35 and 36 show that 
inpatients had a lower quality of life score (p < 0.01) and a higher clinical summary score 
(p < 0.05) relative to outpatients. 
 Clinically significant differences in each of the ten KCCM summary scores are 
outlined in Table XII and separated by patient status.  Clinical improvement and clinical 
decline were seen among aggregates for both inpatients and outpatients. 
 
3.4 Subjective Data 
 Throughout both psychophysiologic assessments, patients were asked to report 
their level of relaxation after each activity (self-relaxation, stressors and subsequent rests) 
using a 5-point Likert scale with 1 being not at all relaxed and 5 being completely 
relaxed.  As shown in Figure 37, patients felt significantly more relaxed after 
biofeedback training for every psychophysiologic assessment activity except for the self-
relaxation (p = 0.15) and the stressful event recall (p = 0.13). 







    
 Before After  
Aggregate Score Biofeedback Training Biofeedback Training p - value
        
    
Physical Limitation 42.8 ± 22.5 46.7 ± 22.4 0.25 
Symptom Stability 56.5 ± 16.3 55.2 ± 19.6 0.82 
Symptom Frequency 61.2 ± 22.8 64.3 ± 24.1 0.41 
Symptom Burden 66.6 ± 19.5 65.8 ± 22.6 0.84 
Total Symptom 64.0 ± 20.2 65.0 ± 22.1 0.77 
Self-Efficacy 85.7 ± 17.7 92.0 ± 11.5 0.16 
Quality of Life 40.4 ± 19.7 40.3 ± 22.6 0.97 
Social Limitation 32.7 ± 28.4 28.1 ± 19.9 0.60 
OVERALL SUMMARY 47.4 ± 14.1 47.5 ± 13.3 0.96 
CLINICAL SUMMARY 57.1 ± 16.2 59.4 ± 16.9 0.49 



















































Figure 35.   KCCM quality of life aggregate score before and after 
biofeedback training in inpatients and outpatients. 
 
Overall, inpatients reported a lesser quality of life than outpatients (p < 











































Figure 36.   KCCM clinical summary aggregate score before and 
after biofeedback training in inpatients and outpatients. 
 
Inpatient clinical summary score was higher than outpatient clinical 
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Table XII.   Clinical Analysis of KCCM Aggregate Scores 
PL = Physical Limitation, SS = Symptom Stability, SF = Symptom Frequency, SB = Symptom Burden, TSS = 
Total Symptom Score, SE = Self-Efficacy, QOL = Quality of Life, SL = Social Limitation, OSS = Overall Summary 



































































































Figure 37.   Self-reported relaxation level throughout psycho-
physiologic assessment before and after biofeedback training. 
 
Patients reported being more relaxed throughout the 
psychophysiologic assessment following biofeedback training (  p < 




relaxing activities.  This analysis showed that patients reported being more relaxed after 
relaxing activities than stressful activities (p < 0.01), independent of biofeedback training.  
Grouped activities were then analyzed before and after biofeedback training, and Figure 
38 shows that patients were significantly more relaxed after biofeedback training for both 
stressful activities (p < 0.001) and relaxing activities (p < 0.01). 
 The same relaxation Likert scale was used to gauge patients’ relaxation levels at 
 the beginning and the end of each training session.  Figure 39 shows that patients were 
more relaxed at the end of training sessions than they were at the beginning.  
  A similar 5-point Likert scale was used to evaluate patients’ mood at the 
beginning and end of each training session.  On this Likert mood scale, 1 represented sad, 
and 5 represented happy.  Figure 40 shows that patients reported being in a better mood 
at the end of biofeedback training sessions. 
 
Inpatients vs. Outpatients 
 Both inpatients and outpatients reported feeling more relaxed after biofeedback 
training for each psychophysiologic assessment activity.  The difference reached 
statistical significance for inpatients with respect to the Serial Sevens (p < 0.05), Rest #2 
(p < 0.01) and Rest #3 (p < 0.05) activities.  Significantly greater relaxation for the 
outpatients was reported following the Stroop Color Word Test (p < 0.05).     
In the grouped analysis of psychophysiologic assessment activities, there was no 
difference between inpatient and outpatient responses to stressors (p = 0.31) or to 
relaxing activities (p = 0.32).  In both cases, a significant training effect was shown.  Both 




























































Figure 38.   Self-reported relaxation level for stressful and 
relaxing psychophysiologic assessment activities before and after 
biofeedback training. 
 
Patients reported being more relaxed following biofeedback training 
for both stressful (      p < 0.001) and relaxing (     p < 0.01) activities 
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Figure 39.   Average self-reported relaxation level throughout 
training sessions. 
 
On average, patients reported being more relaxed at the end of 
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Figure 40.   Average self-reported mood throughout training 
sessions. 
 
On average, patients reported being in a better mood at the end of 
biofeedback training sessions than at the beginning. 
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respect to both stressors (overall p-value = 0.002) and relaxing activities (overall p-value 
= 0.003).  These relationships were only significant for inpatients, however.  Inpatients 
were significantly more relaxed after stressors and relaxing activities after biofeedback 
training (both stressor and relaxing activity p-values < 0.05). 
 
3.5  Clinical Data 
 Clinical data were collected in outpatients only.  As a reference for the remaining 
analyses, Table XIII provides a checklist for what data were collected on each patient in 
the study.  Patients who completed all eight sessions of biofeedback are highlighted in 
gray.   
 
Six Minute Walk Test 
Patients (n = 7) walked an average of 910 ±  421 feet before biofeedback training 
and 961 ± 318 feet after biofeedback training (p = 0.81) as shown in Figure 41.  For 
patients with heart failure, 130 feet is the clinical cut-off for improvement or regression 
in functional capacity,3,91 and when analyzed as individuals using this criterion, Figure 
42 shows that three patients (highlighted in red, blue and green) made clinical 
improvements in their six-minute walk distance (red: 1080 to 1270 feet; blue: 420 to 690 
feet; green: 200 to 500 feet).  
 
Plasma Norepinephrine 
 Figure 43 shows that patients’ average plasma norepinephrine level (n = 8) was 





PT ID SA #1 # T SA #2 6MW NE SF-36 KCCM Tx M R W 
                        
 
IP 1 X 6 X     X X X X X X 
IP 2 X 4      X X X X 
IP 3 X 6 X     X X X X X X 
IP 4 X 6 X     X X X X X X 
IP 5 X 2      X    
IP 6 X 4      X X X X 
IP 7 X 6 X     X X         
IP 8 X 6 X         X X X X 
IP 9 X 1          
IP 10 X 6 X     X X         
IP 11 X 6 X       X X X   X 
IP 12 X 1      X    
IP 13 X 4          
IP 14 X 6 X     X           
IP 15 X 6 X     X X X X X X 
IP 16 X 6 X     X X         
IP 17 X 6 X     X X         
IP 18 X 6 X     X X         
IP 19 X 0      X    
IP 20 X 5      X X X X 
IP 21 X 4      X X X X 
OP 1 X 6 X   X X X         
OP 2 X 5      X X X X 
OP 3 X 6 X X X X X         
OP 4 Consented, but never returned our call to schedule his first appointment… 
OP 5 X 4          
OP 6 Consented, but received a heart transplant before his first appointment… 
OP 7 X 6 X X X X X         
OP 8 X 6 X X X X X         
OP 9 X 6 X X X X X         
OP 10 X 1          
OP 11 X 6 X X X X X         
OP 12 X 6 X X X X X         
OP 13 X 6 X X X X X         






Table XIII.   Data Collected on All Patients Enrolled in the Study 
IP = Inpatient; OP = Outpatient; SA = Stress Assessment (#1 - Before Biofeedback; #2 - After 
Biofeedback); #T = Number of Training Sessions Completed; 6MW = Six Minute Walk Test; NE = Plasma 
Norepinephrine; SF-36 = Short-Form 36; KCCM = Kansas City Cadiomyopathy Questionnaire; Tx = Heart 
Transplant; M = Muscle Function Experiments; R = Beta / Muscarinic Receptors; W = Western Blots 
 
Note: Biological experiments were done if the patient had at least 4 out of 6 biofeedback training sessions 





































Figure 41.   Average six minute walk distance before and after 
biofeedback training. 
 
Average six minute walk distance did not change following 



































Figure 42.   Individual six minute walk distance before and after 
biofeedback training. 
 
Three patients (highlighted in red, blue and green) made clinical 









































Figure 43.   Average plasma norepinephrine level before and after 
biofeedback training. 
 
Average norepinephrine level did not change following biofeedback 
training (n = 8; p = 0.72).   
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training (p = 0.72).  Although not the same three patients who made clinical 
improvements in their six minute walk distance, another three patients’ plasma 
norepinephrine levels decreased (improved) following biofeedback training as shown in 
Figure 44 (red: 1192 to 701 pg/mL; blue: 352-175; green: 296-189). 
 
3.6  Biological Data 
 Tables XIV and XV display detailed and summarized patient demographics, 
respectively, for the groups analyzed in the biological experiments.  A total of  47 
patients were studied, including 12 donors (non-failing – NF), 12 heart failure patients 
(failing), 12 heart failure patients who were hemodynamically supported with a left 
ventricular assist device prior to heart transplant (F + LVAD), and 11 heart failure 
patients who received biofeedback-assisted stress management training (F + biofeedback) 
prior to cardiac transplantation.  Average age among groups ranged from 48 to 56 years 
old, with the majority of patients being white males with dilated cardiomyopathy.  
Average left ventricular ejection fraction for patients in the non-failing group was 61%, 
and for the three failing groups, average LVEF ranged from 12-19%.   
 
Muscle Function 
 Muscle function experiments were conducted in order to test the response of 
freshly dissected trabecular muscles to sympathetic nervous system (beta-adrenergic) 
stimulation.  This was accomplished by adding a synthetic analogue of norepinephrine, 
called isoproterenol (ISO), to the muscles and measuring various contractile parameters.  





































Figure 44.   Individual plasma norepinephrine level before and 
after biofeedback training. 
 
Three patients (highlighted in red, blue and green) had decreased 
levels of plasma norepinephrine following biofeedback training.  
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Status/Diagnosis Age Sex Race LVEF 
NF 71 M W NA 
NF 53 F B NA 
NF 44 F W 57 
NF 18 M W "depressed EF" 
NF 20 M W 57 
NF 61 M NA NA 
NF 60 F W 65 
NF 16 F W NA 
NF 59 M W NA 
NF NA NA NA NA 
NF 67 F W 65 
NF 54 M W 63 
F 66 M O 15 
F 61 M W 10 
F 58 M W 20 
F 60 F W 10 
F 66 M W NA 
F 65 M H 15 
F 61 M W 25 
F 63 F B 10 
F 44 M B 50 
F 50 M W 20 
F 46 M B 25 
F 26 M W 10 
F + LVAD 62 M W 13 
F + LVAD 61 F B NA 
F + LVAD 59 M W 20 
F + LVAD 52 M W NA 
F + LVAD 27 M W 5 
F + LVAD 58 M W 10 
F + LVAD 64 M W 15 
F + LVAD 57 M W 10 
F + LVAD 51 M W 15 
F + LVAD 44 M W NA 
F + LVAD 42 M W 10 
F + LVAD 64 M W 10 
F + BF 58 M W 25 
F + BF 58 M W 15 
F + BF 60 M W 15 
F + BF 53 F B 15 
F + BF 66 M W 10 
F + BF 46 M W 60 
F + BF 21 M H 10 
F + BF 65 M W 20 
F + BF 62 M B 10 
F + BF 66 M W 15 
F + BF 58 M W 15 
Patients who were added to Muscle Function and Western Blot Analyses 
 







      
Group Age Sex Race LVEF Diagnosis 
      
      
  6 M 9 W   
Donor 48 5 F 1 B 61 - 
  1 UNK 2 UNK   
      
   7 W   
Failing 56 10 M 3 B 19 8 DCM 
  2 F 1 H  4 ICM 
   1 "other"   
      
LVAD 53 11 M 11 W 12 7 DCM 
  1 F 1 B  5 ICM 
      
   8 W  7 DCM 
Biofeedback 56 10 M 2 B 19 3 ICM 
  1 F 1 H  1 CONG 












Table XV.   Summarized Patient Demographics for Biological Data 
M = Male; F = Female; UNK = Unknown; W = White; B = Black; H = Hispanic; DCM = 
Dilated Cardiomyopathy; ICM = Ischemic Cardiomyopathy; CONG = Congenital  
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manipulation (adding isoproterenol) and not to underlying differences in muscle function, 
contractile parameters were measured at baseline, and they can be found in Table XVI.  
No significant differences were found among groups for any of the six parameters. 
These same six contractile parameters were also measured following the addition 
of ISO, and results were compared among groups as a percent change from baseline.  
Data from the F + BF group were also analyzed on an individual patient basis.  Figure 45 
shows that there were no significant differences among groups with respect to the resting 
tension response (RT) (p = 0.06), and RT for 9 out of 11 patients in the F + BF group is at 
or approaching non-failing levels. 
Developed tension (DT) results are depicted in Figure 46, and as we expected, 
muscles from failing hearts improved contraction less than muscles from non-failing 
hearts in response to beta-adrenergic stimulation (p < 0.01), and this response recovered 
in the F + LVAD group.  Although not to the same extent as muscles from the F + LVAD 
group, the F + BF muscles also recovered such that there was no significant difference 
between the F + BF group and the non-failing group.  On an individual patient basis, 
three patients in the F + BF showed a developed tension response at the non-failing level 
(IP 4, IP 6, and IP 8), and five patients’ DT response fell somewhere in between failure 
and non-failure (IP 2, IP 3, IP 15, IP 20 and IP 21).  The last three patients in the F + BF 
group had a DT response to isoproterenol that was at the failing level (IP 1, IP 11 and OP 
2). 
Figure 47 shows the time to peak tension (TPT) results.  No significant 
differences were found among groups (p = 0.70), and although the non-failing and failing 







                    
Contractile Parameters NF  Failing  F + LVAD  F + BF 
                    
          
RT (g/mm2) 3.11 ± 0.38  2.75 ± 0.30  2.51 ± 0.33  2.04 ± 0.15 
          
DT (g/mm2) 1.12 ± 0.15  0.99 ± 0.15  1.69 ± 0.25  0.72 ± 0.15 
          
TPT (sec) 0.18 ± 0.01  0.18 ± 0.01  0.19 ± 0.01  0.17 ± 0.00 
          
THR (sec) 0.14 ± 0.00  0.14 ± 0.01  0.14 ± 0.01  0.13 ± 0.00 
          
+dT/dt (g/sec/mm2) 9.11 ± 1.26  10.41 ± 1.31  11.06 ± 1.40  7.70 ± 1.35 
          
-dT/dt (g/sec/mm2) 7.66 ± 1.25  8.85 ± 1.19  9.76 ± 1.19  6.28 ± 1.33 














Table XVI.   Contractile Parameters at Baseline 
NF = Non-failing; F + LVAD = Failing + Left Ventricular Assist Device; F + BF = Failing + Biofeedback; RT = Resting 
Tension; DT = Developed Tension; TPT = Time to Peak Tension; THR = Time to Half Relaxation; +dT/dt = Peak 
Rate of Tension Rise; -dT/dt = Peak Rate of Tension Fall  
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Figure 45.   Resting tension following addition of isoproterenol. 
 
(A) No significant differences were found among groups for the 
resting tension response to isoproterenol (p = 0.06), and (B) the 
majority of patients in the F + BF group had muscles with resting 













































































Figure 46.   Developed tension following addition of isoproterenol. 
 
(A) Muscles taken from failing hearts contracted significantly less 
than muscles taken from non-failing hearts in response to 
isoproterenol (p < 0.05).  (B) Muscles taken from three patients in the 
F + BF group contracted at non-failing levels in response to 
isoproterenol, and five others contracted more than the average of 












































































































Figure 47.   Time to peak tension following addition of 
isoproterenol. 
 
(A) No significant differences were found among groups for time to 
peak tension (p = 0.70), and (B) the majority of patients in the F + BF 











































































































the F + BF group showed that three patients have TPT responses that are at or surpass the 
non-failing level. 
 The results of time to half relaxation (THR) analyses did not show any significant 
differences among groups (p = 0.11) as shown in Figure 48.  The individual analysis of 
patients in the F + BF group showed that the THR response for most of the muscles was 
like that of muscles taken from non-failing hearts, but again, the means from the non-
failing (-30.3%) and failing (-33.4%) groups are very similar. 
 Figure 49 shows that peak rate of tension rise (+dT/dt) was lower in the failing 
group relative to muscles taken from non-failing hearts (p < 0.01).  This response was not 
seen in the F + LVAD or F + BF groups, both of which did not differ significantly from 
the non-failing group.  Also, the three patients in the F + BF group who had a developed 
tension response to isoproterenol that was equivalent to that of muscles from non-failing 
hearts (IP 4, IP 6 and IP 8) were also the three patients whose peak rate of tension rise 
response was at or above the non-failing level. 
 The peak rate of tension fall (-dT/dt) results were very much like peak rate of 
tension rise.  As Figure 50 shows, peak rate of tension fall was lower in the failing group 
relative to the non-failing group (p < 0.01).  Both the F + LVAD group and the F + BF 
group were not significantly different from non-failing hearts.  On an individual patients 
basis, muscles taken from hearts of F + BF inpatients 4, 6 and 8 again looked like 
muscles from the non-failing group with respect to –dT/dt. 
 
Beta-Adrenergic Receptors 
 To further explore the sympathetic nervous system pathway, beta-adrenergic 
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Figure 48.   Time to peak half relaxation following addition of 
isoproterenol. 
 
(A) No significant differences were found among groups for time to 
half relaxation (p = 0.11), and (B) the majority of patients in the F + 















































































































Figure 49.   Peak rate of tension rise following addition of 
isoproterenol. 
 
(A) Muscles taken from failing hearts had a lower peak rate of tension 
rise in response to isoproterenol (p < 0.01) relative to non-failing 
hearts.  (B) Muscles taken from three patients in the F + BF group had 
peak rate of tension rise responses at the level of non-failing muscles.  
These were the same three patients whose developed tension response 

















































































































Figure 50.   Peak rate of tension fall following addition of 
isoproterenol. 
 
(A) Muscles taken from failing hearts had a lower peak rate of tension 
fall in response to isoproterenol (p < 0.01) relative to non-failing 
hearts.  (B) Muscles taken from three patients in the F + BF group had 
peak rate of tension fall responses at the level of non-failing muscles.  
These were the same three patients whose developed tension and peak 

















































































































receptors were measured among non-failing (NF), failing, F + LVAD and F + BF groups.  
Once again, our group of interest, the F + BF group, was also analyzed on an individual 
patient basis.  As shown in Figure 51, beta receptor density was significantly lower in 
failing hearts (p < 0.05) and recovered in failing hearts with LVAD support.  Beta 
receptor density in the F + BF group did not recover like the F + LVAD group, but rather 
was significantly less than that of the non-failing hearts (p < 0.05).  Individually, three 
patients in the F + BF group showed beta receptor recovery at the non-failing level (IP 1, 
IP 8 and IP 15).  Only one of these patients (IP 8) was one of the patients whose 
developed tension response to isoproterenol was also at the non-failing level.  
 Binding affinity for beta-adrenergic receptors was also analyzed among groups by 
measuring the dissociation constant (Kd), and Figure 52 shows that no significant 
differences were found (p = 0.06).  The overall p-value was very close to being 
significant, and groups with the lowest and highest mean Kd were the F + LVAD (31.4 ± 
12.9 pM) and F + BF group (52.3 ± 21.8), respectively.  Individual patient analysis for 
the F + BF group showed that half of the patients had a Kd that was 40pM or below, and 
the other half of the patients had a Kd that was much higher, at 60pM or above. 
 
Muscarinic Receptors 
 To analyze the contribution of the parasympathetic nervous system, muscarinic 
receptor density and Kd were also measured.  As shown in Figure 53, muscarinic 
receptor density was significantly higher in the failing (p < 0.01) and F + LVAD (p < 
0.001) groups relative to NF hearts.  There was no difference between the NF and F + BF 
groups.  With the exception of one statistical outlier, highlighted in white, most patients  
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Figure 51.   Beta-adrenergic receptor density. 
 
(A) The density of beta-adrenergic receptors was significantly lower in 
the failing and F + BF groups compared to beta receptor density in 
non-failing hearts (p < 0.05).  (B) Three patients in the F + BF group 
showed beta-adrenergic receptor densities at the non-failing level.  
Only one of these patients was also one whose developed tension 






















































































Figure 52.   Binding affinity for beta-adrenergic receptors. 
 
(A) Beta-adrenergic receptor Kd was not significantly different among 
groups (p = 0.06).  (B) Half of the patients in the F + BF group had 






































































Figure 53.   Muscarinic receptor density. 
 
(A) Muscarinic receptor density was significantly higher in the failing 
(p < 0.01) and F + LVAD (p < 0.001) groups relative to non-failing 
hearts.  The F + BF group was not significantly different from the non-
failing group.  (B) Most patients in the F + BF group had muscarinic 


























































































in the F + BF group had muscarinic receptor densities at or just above the non-failing 
level. 
 Figure 54 shows that no significant differences were found among groups with 
respect to binding affinity for muscarinic receptors (p = 0.07).  This Kd data almost did 
reach statistical significance, with the highest and lowest mean Kd’s coming from the 
non-failing (119.9 ± 33.8 pM) and F + LVAD (230.1 ± 112.9 pM) groups.  In the F + BF 
group, most muscarinic receptor Kd’s were at or just below the mean of the non-failing 
group, with the exception of two much higher values and one outlier Kd of 405.6 pM. 
 
Calcium-Cycling Proteins 
 With calcium being a vital component of muscle contraction, proteins that help to 
cycle calcium in and out of the sarcoplasmic reticulum and in and out of the cell itself 
were measured.  In all cases, calcium-cycling proteins were normalized to calsequestrin, 
a protein that has been shown not to change in heart failure.27,53,83   
 Figure 55 shows that no significant differences were found among groups with 
respect to the sarcoendoplasmic reticulum calcium ATP-ase (SERCA) protein (p = 0.62).    
Variable levels of SERCA protein were found in the F + BF group.  
No significant differences among groups were found in sodium-calcium 
exchanger (NCX) protein levels (p = 0.73), as shown in Figure 56, and the F + BF group 
presented with variable NCX levels, most of which were at or above the non-failing 
average. 
 With average values of 0.47 ± 0.19, 0.27 ± 0.14 and 0.36 ± 0.22 relative 
densitometric units (RDU), the failing, F + LVAD and F + BF groups, respectively, had  
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Figure 54.   Binding affinity for muscarinic receptors. 
 
(A) Muscarinic receptor Kd was not significantly different among 
groups (p = 0.07).  (B) Most patients in the F + BF group had Kd’s 







































































Figure 55.   SERCA/CALQ. 
 
(A) There were no significant differences in SERCA protein among 
groups (p = 0.62).  (B) SERCA protein levels in the F + BF group 






































































































































































































Figure 56.   NCX/CALQ. 
 
(A) There were no significant differences in NCX protein among 
groups (p = 0.73).  (B) NCX protein levels in the F + BF group were 
variable, however most were at or above the non-failing level.   
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significantly lower ryanodine receptor (RYR) protein levels than the non-failing group 
(0.75 ± 0.26 RDU; overall p < 0.001).  Figure 57 highlights these differences and shows 
the individual variability in the F + BF group.  One F + BF patient had RYR levels at the 
non-failing level, and two others were approaching the non-failing average. 
 
3.7  Correlation Data 
 In order to determine whether patients who were successful with biofeedback 
were the same patients who showed changes in the biology of the heart, each 
psychophysiologic variable that changed following biofeedback training was correlated 
with each changing biological variable.  These correlation analyses were performed using 
six patients (IP 1, IP 3, IP 4, IP 8, IP 11, IP 15).  There were eleven patients in the 
biofeedback group on whom biological data were collected (Tables XIV and XV), but 
only six of these patients also had before and after biofeedback training data (these six 
patients completed all eight sessions of biofeedback) (Table XIII).  Linear regression 
analyses were also performed, and the results (p-values) are summarized in Table XVII.  
No statistically significant relationships were found.   
 The two correlations highlighted in bold boxes in Table XVII were not significant 
(p > 0.05), however both included a point outside the 95% confidence interval.  This 
point was from the same patient in each relationship, IP 11.  Because IP 11 is the only 
patient with congenital heart disease in the study, these two relationships were analyzed 
both with and without IP 11, and removing this patient created highly significant 
relationships between these two sets of variables. 























































Figure 57.   RYR/CALQ. 
 
(A) RYR levels were significantly lower in the failing (p < 0.01), F + 
LVAD (p < 0.001) and F + BF (p < 0.001) groups relative to the non-
failing group.  (B) RYR protein levels in the F + BF group were 
variable, and most were below the failing level.  Three patients, 
however, showed RYR levels at or approaching the non-failing level.  























































     
 DT (ISO) B-AR MR RYR 
          
     
Resp Rate (in Session 8) 0.98 0.71 0.79 0.17 
Resp Rate (% Change) 0.17 0.47 0.24 0.85 
SDNN (in Session 8) 0.30 0.96 0.30 0.87 
SDNN (% Change) 0.45 0.34 0.23 0.37 
Agg. CV React (% Change) 0.91 0.61 0.11 0.08 
Agg. CV Recover (% Change) 0.22 0.50 0.26 0.72 
Homework 0.87 0.16 0.56 0.99 











Table XVII.   Biofeedback vs. Biology Correlation Data 
From top to bottom, biofeedback variables analyzed include: Average 
respiration rate during the first 5-minute self-relaxation of session 8; 
Respiration rate as a percent change from the first 5-minute self-relaxation of 
session 1 to the first 5-minute self-relaxation of session 8; Average SDNN 
during the first 5-minute self-relaxation of session 8; SDNN as a percent 
change from the first 5-minute self-relaxation of session 1 to the first 5-minute 
self-relaxation of session 8; Aggregate cardiovascular reactivity as a percent 
change difference (session 8 minus session 1); Aggregate cardiovascular 
recovery as a percent change difference (session 8 minus session 1); 
Number of homework sheets turned in. 
 
DT (ISO) = % change in developed tension following the addition of 
isoproterenol; B-AR = Beta-adrenergic receptor density; MR = Muscarinic 


























































































Figure 58.   Relationship between respiration rate and ryanodine 
receptor protein expression. 
 
(A) WITH IP 11 – There is no significant relationship between 
average respiration rate during the first 5-minute self-relaxation of 
session 8 and ryanodine receptor protein expression (p = 0.17; R2 = 
0.52).  (B) WITHOUT IP 11 – Patients who were breathing at lower 
rates in session 8 had greater expression of ryanodine receptor protein 
(p = 0.02; R2 = 0.97).  
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5-minute self-relaxation of session 8 and expression of the ryanodine receptor protein, 
both with and without IP 11.  While no significant relationship existed in the presence of 
IP 11 (p = 0.17; R2 = 0.52), removing the IP 11 data point created a significant 
correlation in which patients who were breathing at lower rates following biofeedback 
training had greater expression of ryanodine receptor protein (p = 0.02; R2 = 0.97). 
 A significant relationship between percent change in respiration rate and 
developed tension in response to isoproterenol also emerged when IP 11 was removed, as 
shown in Figure 59 (p = 0.01; R2 = 0.90).  Specifically, patients who lowered their 
respiration the most (negative percent change) had greater developed tension responses to 
isoproterenol. 
 In addition to relationships between biofeedback and biological data, correlations 
between transplant wait time following biofeedback training and the biological variables 
analyzed above were also explored.  Table XVIII displays the number of days patients 
waited for transplant following their participation in the biofeedback study, and Table 




























































































Figure 59.   Relationship between respiration rate and developed 
tension response to isoproterenol. 
 
(A) WITH IP 11 – There is no significant relationship between percent 
change in respiration rate and developed tension in response to 
isoproterenol (p = 0.17; R2 = 0.41).  (B) WITHOUT IP 11 – Patients 
who lowered their respiration rate the most had greater developed 































IP 3 37 
IP 4 40 
IP 8 7 
IP 11 257 
IP 15 230 
    


























     
 DT (ISO) B-AR MR RYR 
          
     
BF → Tx (days) 0.40 0.65 0.60 0.09 
          
Table XVIIII.   Transplant Wait Time vs. Biology 
Correlation Data 











 Self-regulation techniques have been explored in the treatment of heart failure 
prior to this study.  Mindfulness training has been shown to reduce anxiety and 
depression and to improve clinical symptoms in patients with heart failure.106  Quality of 
life has been shown to improve following both relaxation training21,124 and meditation26, 
and meditation has also been shown to reduce circulating norepinephrine.26 
 
4.1 Biofeedback in End-Stage Heart Failure Patients 
Although the potential for other mind-body therapies to play a role in heart failure 
has been shown, there have only been a few studies exploring the efficacy of biofeedback 
training in patients with documented heart failure, and therefore the ability for heart 
failure patients to learn biofeedback was unknown.   
 
Respiration Rate 
 Respiration rate was the first physiologic modality focused on in the biofeedback- 
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assisted stress management training protocol.  Patients were taught to breathe from the 
diaphragm as opposed to the chest and were encouraged to breathe slowly and deeply.  
Over the course of the study, patients were able to progressively decrease their breathing 
rate, resulting in a significantly lower rate after only two training sessions.  Before 
biofeedback training, patients’ average breathing rate was 14.9 ± 2.9 breaths per minute, 
and after biofeedback training, average respiration rate decreased to 9.4 ± 2.7 breaths per 
minute.  This result is similar to a study done by Bernardi and colleagues in 1998, 
however that study used diaphragmatic breathing training only, not biofeedback.   
Bernardi showed that in nine heart failure patients practicing diaphragmatic 
breathing at home for one hour every day for a month, spontaneous breathing rate 
dropped from 13.4 ± 1.5 to 7.6 ± 1.9 breaths per minute.7  While the absolute change in 
respiration rate is similar in our study and the Bernardi study (~ 5.5 breaths per minute), 
patients in the Bernardi study had lower breathing rates both before and after 
intervention.  What was not reported in Bernardi’s study, however, are the clinical 
demographics of these nine heart failure patients, and it is possible that our heart failure 
population (NYHA class III or IV, average LVEF of 23%) had more severe disease. 
 Other studies exploring the benefits of slower breathing in heart failure patients 
did not use biofeedback and did not report respiration rate before and after intervention, 
but showed that relative to a control group of heart failure patients, lowering respiration 
rate results in decreased dyspnea121, improved exercise tolerance6,121, and lower blood 
pressure95. 
 
Digital Peripheral Temperature 
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  Digital peripheral temperature was measured in this study as an indirect correlate  
of peripheral vasoconstriction.  When a person is relaxed, their blood vessels dilate, 
allowing more warm blood to pass through.  Because biofeedback cannot directly 
measure blood vessel diameter, it measures finger temperature instead.  This is because 
the fingers have a dense network of blood vessels with relatively little surrounding tissue.  
As a result, changes in temperature occur relatively more rapidly in the fingertips.103   
We expected that biofeedback-assisted stress management training would 
augment parasympathetic nervous system activity, causing blood vessels to dilate and 
digital peripheral temperature to increase.  This is consistent with the findings of Moser 
and colleagues in 1997.  Moser showed that heart failure patients significantly increased 
their finger temperature from 91.5 ± 4.7°F to 94.6 ± 3.1°F after only one session of 
biofeedback combined with modified progressive muscle relaxation and imagery of hand 
warmth.86 
We found that there was essentially no change in finger temperature following 
biofeedback training.  Patients’ average finger temperature was 89.9 ± 4.1°F before 
training and 89.8 ± 5.0°F after training.  What is important to note is that while 
participating in this study, patients were still receiving standard medical management for 
their heart failure, and except for 3 patients whose medical records were unavailable 
(therefore we do not know what medications they were taking), all patients in the study 
were on some type of medication with vasodilatory properties.  This was not the case in 




Heart Rate Variability 
 Autonomic imbalance is a hallmark of heart failure, reflecting a decreased 
resilience in the cardiovascular system to meet the demands of the environment, and is 
associated with increased morbidity and mortality.11,60  In recent years, heart rate 
variability (HRV) has become a useful tool to measure autonomic balance, and depressed 
HRV has been shown to be a marker of poor prognosis in patients with heart failure.90 
In this study, heart rate variability was measured by calculating the standard 
deviation of the inter-beat intervals (SDNN).  This time domain measure is the most 
commonly used marker of autonomic function because it reflects all biological 
oscillations that lead to variations in heart rate.110  On average, patients’ SDNN 
significantly increased following biofeedback training, going from 32 ± 22 msec before 
biofeedback training to 44 ± 23 msec after biofeedback training.  
The only other study showing the heart failure patients can use biofeedback to 
increase HRV came out in 2009 and showed that SDNN increased significantly following 
cardiorespiratory biofeedback training but only in patients with ejections fractions equal 
to or above 31%.107  Disease severity was greater in our study (average LVEF 23 ± 15%), 
and it is now the first to show that end-stage heart failure patients with ejection fractions 
at or below 30% can increase their HRV following biofeedback training. 
Furthermore, 25% of patients in the current study (5 out of 20) increased their 
SDNN from an unhealthy range (0-50 msec) to a moderately healthy range (50-100 
msec) as defined by the Task Force of the European Society of Cardiology and the North 
American Society of Pacing Electrophysiology.110  Movement into a higher category has 
been shown to increase a patient’s probability of survival.  In 1987, Kleiger and 
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colleagues found a 4-fold increase in the relative risk of death in 808 patients after 
myocardial infarction with low SDNN (≤ 50msec) compared to those with high SDNN (≥ 
100 msec), and HRV remained the strongest predictor of death after accounting for 
demographics, medications, and various clinical factors.60 
 
Psychophysiologic Reactivity and Recovery 
 In this study, instantaneous heart rate was analyzed before, during and after 
mental stress tasks in a psychophysiologic assessment before and after biofeedback 
training in an effort to measure both reactivity to and recovery from mental stress.  
Studies have shown that stress reactivity is associated with illness severity and is a 
predictor of later illness, especially cardiovascular disease.63,114 
We expected that patients would react less to psychological stress following 
biofeedback training, and that this would be manifest as less of an increase in heart rate 
during mental stressors.  Several studies have shown that biofeedback training can be 
used to control blood pressure during tests of mental stress32,45,64,84, however we did not 
measure blood pressure in the current study.  Using heart rate to quantify cardiovascular 
reactivity, we found no significant change following biofeedback training.  We also did 
not show an increase in recovery from mental stress following biofeedback training.  
Instead no significant differences were found. 
 There are several limitations to the measurement of cardiovascular reactivity in 
the current study.  First, the same stressors were used in the same order in both 
psychophysiologic assessments.  Patients were informed prior to the last session that the 
second psychophysiologic assessment was going to be the same as they experienced in 
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the first session.  It is difficult to know whether this knowledge would cause patients to 
be more relaxed in the second assessment because they know what is coming or if it 
could potentially cause patients to be more nervous, anticipating the stressors because 
they know what they are. 
It is also necessary to consider the effect of the same team (biofeedback 
technician and therapist) administering the psychophysiologic assessment in both the first 
and last biofeedback sessions.  It is possible that patients may have grown comfortable 
with the biofeedback team, and again, one could argue that this could make the patient 
more calm the second time around or it could add pressure to perform since it is clear to 
the patient that they should be less reactive following biofeedback training.  Ruminating 
about performance in between tasks would certainly keep patients from recovering.  One 
might also speculate that comfort with the biofeedback team could allow patients to be 
more vulnerable over time, actually responding more (reacting more) following 
biofeedback training.  In this case, patients should still recover more quickly if they were 
successful with biofeedback training. 
 
Homework 
 Patients were provided with relaxation CDs and handheld thermometers and 
asked to practice at least 20 minutes each day.  Sheets were provided to record daily 
stress levels and as well as finger temperature before and after relaxation practice.  These 
daily record sheets were collected at the beginning of each visit.  One limitation to this 
approach is that digital peripheral temperature did not significantly change in the office, 
and therefore it is unclear if using this modality for home practice actually helped 
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patients.  One might imagine that it was a source of frustration if patients felt unable to 
increase their finger temperature and therefore unable to succeed.  On the other hand, 
some studies have shown that patients who practice a treatment do so because they find 
the treatment to be useful.  Overall, 14 out of the 20 patients who finished all eight 
sessions of biofeedback (70%) completed some amount of homework. 
 
Subjective Data 
 Patients were asked to self-report their level of relaxation after every activity 
(stressful and relaxing) in each psychophysiologic assessment.  When stressors and 
relaxing activities were grouped together, patients reported being more relaxed during 
both types of activities after biofeedback training as compared to before training.  One 
limitation to interpretation of this data is that patients knew they were in a study of 
relaxation and stress management, so perhaps they reported what was expected or what 
they felt was “the right answer.”  Without a validated measure of relaxation and a control 
group, there is no way to know if this response would be different in a group of heart 
failure patients who did not receive biofeedback-assisted stress management training or 
in any cohort based simply on test-retest effects. 
 
Inpatients vs. Outpatients 
 With respect to respiration rate, inpatients made significant improvement after 
two biofeedback training sessions whereas outpatients required four training sessions in 
order to significantly lower their breathing rate.  This difference may be due to the 
frequency with which patients were trained.  Inpatients by definition were waiting for a 
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heart transplant in the hospital because they were the sickest of the patients on the 
transplant list and therefore the most likely to receive a heart transplant.  These patients 
were seen more frequently (twice a week for four weeks) in order to have sufficient time 
to get through the entire biofeedback-assisted stress management training protocol before 
the patients came to transplant.  Outpatients were seen once a week for eight weeks, and 
so perhaps even if they practiced on their own as encouraged, they would have benefitted 
more from more frequent respiratory biofeedback training with a certified psychologist 
present. 
 Across biofeedback sessions, outpatients showed a significant increase in SDNN 
that was not present in the inpatient sample.  Although not a significant difference, this 
may be due to the fact that SDNN before biofeedback training was lower in the outpatient 
cohort relative to the inpatients.  Because lower SDNN is a marker of poorer 
cardiovascular resilience and prognosis, this does not necessarily support the idea that 
inpatients are sicker than outpatients. 
 The same limitations exist with respect to cardiovascular reactivity and recovery 
when analyzed based on patient status, but the fact that inpatients had less time in 
between psychophysiologic assessments may have played a role in any differences 
between cohorts.  Although not statistically significant, there seemed to be an inverse 
reactivity relationship between inpatients and outpatients before and after biofeedback 
training, wherein inpatients tended to react more following biofeedback training, and 
outpatients tended to react less.  Perhaps inpatients remembered the stressors more than 
outpatients and anticipated them, thereby increasing reactivity. 
In addition to the difference in the time course of training between inpatients and 
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outpatients, the treatment setting is also quite different.  One might imagine that 
outpatients are living at home waiting for transplant and are therefore dealing with more 
real-life stressors than inpatients who are in a controlled hospital environment.  As a 
result, perhaps they have more practice translating the relaxation and stress management 
skills learned in the study to everyday life such that laboratory mental stress tasks were 
not as arousing to this cohort after biofeedback-assisted stress management training.   
Although they tended to react more, inpatients were shown to recover from mental 
stress significantly more than outpatients, and this did not change with biofeedback 
training.  If taken as a measure of success with biofeedback, then greater cardiovascular 
recovery in the inpatient cohort might suggest that the inpatients were more successful 
than the outpatients.  Again, the analysis of cardiovascular reactivity and recovery is 
complex, and it is possible that differences lie solely within the method of measurement 
and not a true difference.70    
Surprisingly, with respect to the amount of homework completed, outpatients on 
average turned in more daily record sheets than inpatients.  Assuming an equal 
probability that patients who did their homework would turn it in, this means that 
outpatients practiced more than inpatients.  Because inpatients were living in the hospital, 
often with no visitors other then hospital staff, it was expected that they would practice 
more often just due to a lack of other things to do.  Perhaps practice in between sessions 
was more relevant to this cohort because there was more time in between sessions.  Of 
course the flaw in this approach is that is doesn’t account for how many homework sheets 
each patient could have turned in.  Perhaps looking at the percentage of homework turned 
in based on the total number of homework sheets the patient could have turned in would 
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reflect a different trend.  Certainly the length of participation in the study varies between 
cohorts (inpatients are in the study for four less weeks), and therefore if an inpatient 
turned in the same number of daily record sheets as an outpatient, it would mean that the 
inpatient practiced more often. 
 
4.2 The Effect of Biofeedback on Quality of Life 
In this study, no significant changes in general or heart failure-specific quality of life 
(QOL) were observed following biofeedback training.  When separated by patient status, 
however, some QOL differences did emerge.  Keep in mind that in all cases, higher 
scores reflect a greater level of functioning.  
On the SF-36, inpatients reported a lower social functioning score than outpatients, 
and this did not change with biofeedback.  This makes sense because inpatients were 
waiting for a heart transplant in the hospital, and therefore probably had fewer 
opportunities to socialize than patients waiting for transplantation at home.  Inpatients 
also reported a greater general health score as compared to outpatients, and this did not 
change with biofeedback.  This may also be a result of inpatients living in the hospital 
because they have access to immediate care whenever they have a question, need a 
medication adjusted, etc. 
With respect to the heart failure-specific Kansas City Cardiomyopathy 
Questionnaire, inpatients reported a lower quality of life score than outpatients which did 
not change with biofeedback training.  Once again, this could be a result of inpatients 
living in the hospital while waiting for a heart transplant, perhaps missing the social 
connections and freedoms that come with living at home.  On the KCCM, the clinical 
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summary score is an average of Physical Limitation Score and Total Symptom Score, 
reflecting how the patient is feeling physically with his or her heart failure.  Inpatients 
reported higher clinical summary scores than outpatients, and this did not change with 
biofeedback.  Again, one might imagine that access to around-the-clock medical care 
help inpatients manage the symptoms of heart failure better than outpatients living at 
home. 
 One limitation of the evaluation of quality of life in this study is the lack of an 
appropriate control group.  We know that these patients’ heart failure is progressing over 
time, and one might expect quality of life scores to decline as a result.  Perhaps 
biofeedback kept heart failure patients in this study on an even keel such that we are 
actually underestimating the effect of biofeedback on quality of life. 
 
4.3 The Effect of Biofeedback on Clinical Course 
Clinical data were collected in outpatients only.  Inpatients were unable to get out of 
bed to do the six minute walk test, and blood could not be drawn for plasma 
norepinephrine for logistical reasons.  
Plasma norepinephrine was taken as a marker of sympathetic nervous system 
activity.  High levels of circulating norepinephrine have become a biomarker of heart 
failure due to excess sympathetic input, and because we were teaching patients to 
decrease sympathetic activity, we expected plasma norepinephrine levels to decrease 
after biofeedback training.  What we saw was that average plasma norepinephrine levels 
did not change following biofeedback training, however plasma norepinephrine did 
decrease in three of the eight patients. 
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 Six-minute walk distance, a common measure of functional capacity in heart 
failure patients3, also showed no significant change following biofeedback training.  This 
finding is consistent with that of Swanson et al. who showed that exercise tolerance did 
not improve in patients with a left ventricular ejection fraction ≤ 30%.107  The patients in 
the current study who completed the six-minute walk test all had ejection fractions at 
30% or below.  A study by Luskin in 2002 showed that a combination of biofeedback and 
stress management was associated with an increase in exercise tolerance (on average 
patients walked 175 feet further after the intervention), however again the patients in that 
study had New York Heart Association class I to “very early class III” heart failure, a 
population that has less severe disease relative to the patients in the Swanson and current 
studies.73 
 Even though average distance walked did not change with biofeedback training, 
the clinical cutoff for improvement or regression in functional capacity is 130 feet3, and 
by this criterion, three patients showed clinical improvement in exercise tolerance.  These 
were not the same three patients who showed decreased levels of circulating 
norepinephrine. 
 
4.4 The Effect of Biofeedback on Myocardial Remodeling 
In this study, we hypothesized that biofeedback could reverse the heart failure 
phenotype.  We measured biological changes that we already know occur in heart failure 
and recover with LVAD support, including muscle contraction, beta-adrenergic and 
muscarinic receptor densities, as well as some of the calcium cycling proteins 
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downstream of these receptors.  We hypothesized that biofeedback would also show 
recovery of such myocardial remodeling. 
 
Muscle Function 
 Muscle function experiments were conducted in order to measure the response of 
individually dissected trabecular muscles to sympathetic nervous system stimulation.  
After finding the length at which each muscles produced its greatest contraction (Lmax), 
six contractile parameters were analyzed both at baseline as well as after a single dose of 
isoproterenol (ISO), a synthetic analogue of norepinephrine.  All comparisons were made 
relative the non-failing group, and there were no significant differences in any of the six 
contractile parameters at baseline.  This means that any differences we saw were due to 
our experimental manipulation (adding isoproterenol) and not to some initial difference 
in muscle function.   
For all six contractile parameters, the response to isoproterenol (ISO) was 
measured as a percent change from baseline.  Because it is known that sympathetic 
nervous system activity increases heart rate and force of contraction, we expected to see 
the following changes in the non-failing (NF) group: (1) Resting tension (RT) is the 
amount of tension a muscle generates at rest and was expected to decrease, (2) Developed 
tension (DT) is the amount of force a muscle generates during contraction and was 
expected in increase, (3) Time to peak tension (TPT) is the amount of time it takes for a 
muscle to reach the peak of contraction once it begins to contract and was expected to 
decrease, (4) Time to half relaxation (THR) is the amount of time it takes for a muscle to 
get from the peak of contraction to the halfway point of relaxation and was expected to 
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decrease, (5) Peak rate of tension rise (+dT/dt) is the point at which the muscle is 
contracting the fastest and was expected to increase, and (6) Peak rate of tension fall (-
dT/dt) is the point at which the muscle is relaxing the fastest and was expected to 
increase.  We know that these effects are depressed in muscles from patients with heart 
failure and to recover in muscles from patients with LVAD support.  We hypothesized 
that the magnitude of the outlined changes will not be significantly different between the 
non-failing and failing + biofeedback (F + BF) groups. 
The RT response to ISO decreased as expected with no significant differences 
among groups.  Statistical significance was almost reached, however, and with mean 
values of -11.1 ± 6.0% and -10.6 ± 3.2%, the failing and F + LVAD groups showed less 
of a decrease in resting tension relative to the NF and F + BF groups (-16.1 ± 8.8% and -
15.3 ± 2.9, respectively). 
The DT response to ISO increased across all four groups, however muscles taken 
from failing hearts contracted significantly less than muscles taken from non-failing 
hearts.  These results were as expected.  In support of our hypothesis, there was no 
significant difference in DT response to ISO between the NF and F + BF groups, 
suggesting that biofeedback is associated with recovery of the functional response to ISO 
in individual cardiac muscles.  On an individual patient basis, muscles taken from eight 
patients in the F + BF group contracted more than the average failing level, with muscles 
from three of these patients contracting at or above the non-failing level. 
As expected, TPT and THR both decreased in response to ISO.  No significant 
differences were found among groups with respect to either contractile parameter. 
 141
In order for heart rate to increase, the rate of contraction and relaxation must 
increase, and these results were shown in the peak rate of tension rise and fall responses 
to ISO across all four groups.  As expected, the +dT/dt and -dT/dt responses were 
significantly lower in the failing group and recovered in the F + LVAD group.  Although 
not to the same degree as the LVAD group, muscles in the F + BF group were not 
significantly different from muscles in the non-failing group with respect to +dT/dt or -
dT/dt.  For the three patients in the F + BF group whose developed tension response to 




 Several studies have shown that beta-adrenergic receptor density is decreased in 
human heart failure, and that this reduction is reversed with LVAD support.  In 2001, 
DiPaola and colleagues showed a 53% decrease in beta receptor density in failing human 
hearts relative to non-failing human hearts.27  This confirmed the much earlier landmark 
study by Bristow and colleagues which also showed that there about 50% less beta 
receptors in failing human hearts than there are in non-failing human hearts.19  Ogletree-
Hughes et al. showed that beta-adrenergic receptor density in hearts with LVAD support 
was comparable to that in non-failing hearts.92  
In the current study, we expected to replicate these results, showing a decrease in 
beta-adrenergic receptor density that is reversed in heart failure patients with an LVAD, 
and we hypothesized that the F + BF group would also show a recovery of beta-
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adrenergic receptors, especially since we saw recovery in the functional response 
(developed tension response to ISO). 
Although the magnitude of change was less (32%) than in previous studies (50% 
and 53%), we saw a significant decrease in beta-adrenergic receptor density in failing 
human hearts relative to non-failing hearts.  We showed no significant difference in beta-
receptor density between the non-failing and F + LVAD groups, confirming the recovery 
of LVAD-supported failing hearts shown in other studies.  Beta receptor density in the F 
+ BF group was significantly lower than that of the non-failing group, suggesting that 
biofeedback is not associated with the recovery of beta-adrenergic receptor density.   
On an individual basis, three patients in the F + BF group did show recovery of 
beta-adrenergic receptors such that they were at or even above the non-failing average.  
Only one of these patients was one who also exhibited a developed tension response to 
isoproterenol at the non-failing level.   
One can speculate that increased levels of circulating norepinephrine in heart 
failure patients may play a role in decrease in beta-adrenergic receptor density.  If all of 
the excess NE were to bind the beta-receptors, the subsequent response would use up a 
ton of cellular ATP.  Studies have shown normalization of plasma norepinephrine in 
LVAD patients, and so perhaps this is responsible for beta-adrenergic receptor recovery.  
This might also be a potential mechanism of action for biofeedback considering that 
some patients did exhibit beta receptor recovery.  These patients were inpatients, 
however, and therefore plasma norepinephrine was not collected.  In order to answer this 
mechanistic question, one would have to show a relationship between normalized 
(increased) beta receptor density and decreased plasma norepinephrine levels following  
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biofeedback training. 
In receptor binding studies, the relationship between the rate of formation and 
dissociation of the ligand-receptor complex is called the equilibrium dissociation constant 
(Kd).  Kd is the reciprocal of the affinity of a ligand for a receptor, and so Kd was 
measured across groups in this study as an inverse measure of binding affinity.  This 
means that lower Kd values for a particular receptor indicate a higher binding affinity of 
the ligand for the receptor.  One might imagine that functional changes can be due to an 
increased number of the receptor mediating the response or to an increased affinity of 
ligand for the receptor. 
Results show no significant changes in beta-adrenergic receptor Kd across groups.  
In the F + BF group, however, half of the patients exhibited a much higher Kd than the 
other half of patients. 
 
Muscarinic Receptors 
 Muscarinic receptor expression in the human heart is not nearly as well-
characterized (in health or disease) as is the expression of beta-adrenergic receptors.  
Early studies of muscarinic receptor density in humans showed no significant differences 
in muscarinic receptor density between failing and non-failing hearts.  In 1990, Bohm et 
al. measured muscarinic receptor density in 16 failing and 5 non-failing human hearts 
using radioligand binding with a tritiated antagonist and showed that although there were 
less receptors in failing hearts (211 ± 22 fmol/mg protein vs. 275 ± 21 fmol/mg protein in 
non-failing hearts) the difference was not statistically significant.15  The opposite result 
was shown by Le Guludec and colleagues who used positron emission tomography (PET) 
 144
to non-invasively measure myocardial muscarinic receptors in 20 heart failure patients 
and 12 normal controls.  This study showed that average muscarinic receptor density was 
significantly higher in the patients with heart failure relative to controls (34.5 ± 8.9 
pmol/mL and 25.0 ± 7.8 pmol/mL, respectively).65 
 In the current study, we showed that muscarinic receptor density was significantly 
greater in failing human hearts relative to non-failing hearts (166.1 ± 45.9 fmol/mg 
protein vs. 92.1 ± 25.2 fmol/mg protein).  LVAD-supported hearts exhibited even more 
muscarinic receptors, with a density of 221.1 ± 61.3 fmol/mg protein.  Muscarinic 
receptor density in the F + BF group (123.2 ± 26.4 fmol/mg protein) was not significantly 
different from that of the non-failing group. 
 The only other study to measure muscarinic receptor density in heart failure 
patients with an LVAD came out of the Moravec laboratory last year, and it confirmed 
the results of the current study, showing a similar increasing relationship in muscarinic 
receptor density across non-failing, failing and LVAD-supported hearts.42   
One might speculate that muscarinic receptors are up-regulated in failing hearts in 
an attempt to combat sympathetic nervous system (SNS) hyperactivity by increasing 
parasympathetic nervous system input to the cardiovascular system.  Because the LVAD 
has been shown to reverse remodel the cellular and molecular changes associated with 
SNS hyperarousal, it would make sense to think that the need for elevated muscarinic 
receptors would go away, and there would be a normalization of muscarinic receptor 
density in LVAD-supported hearts.  Instead, muscarinic receptor density was shown to 
further increase in the F + LVAD group.  This may suggest that parasympathetic nervous 
system hypoactivation does not recover in patients with heart failure supported by an 
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LVAD.  Because no significant difference was found in muscarinic receptor density 
between the non-failing and F + BF groups, this might also suggest that biofeedback is 
associated with a normalization of muscarinic receptors in patients with end-stage heart 
failure.   
When the muscarinic receptor Kd was analyzed across groups, the F + LVAD 
group was significantly higher than the non-failing group.  This means that binding 
affinity for muscarinic receptors is lower in LVAD-supported hearts.  As previously 
discussed, the density of muscarinic receptors increased in this group.  What is unknown 
is the temporal relationship between receptor density and receptor affinity.  Perhaps 
muscarinic receptor density increased and then affinity decreased to compensate for an 
increase in signal transmission.  Or maybe binding affinity for muscarinic receptors 
decreased and then receptor density increased in an attempt to restore the signal.   
It is also possible that the differences in muscarinic receptor Kd are due to a 
difference in the distribution of muscarinic receptor subtypes, and it would be interesting 
to measure these subtypes across all four groups of patients going forward.  While the 
exact reason for the difference in Kd in the F + LVAD group is unclear, our group of 
interest, the F + BF group, did not show a significant difference in muscarinic receptor 
binding affinity relative to non-failing hearts. 
 
Calcium Cycling Proteins 
 With the exception of the ryanodine receptor, calcium cycling proteins were 
chosen because the changes in heart failure and heart failure with LVAD support were 
well-documented and well-understood.  Specifically, SERCA is decreased and NCX is 
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increased in failing human hearts, leading to decreased contractile function.  These 
changes in calcium cycling proteins are reversed and contractile function is improved in 
LVAD-supported hearts.28  We expected to replicate these results in the current study, 
and we hypothesized that hearts in the F + BF group would exhibit reverse remodeling of 
calcium cycling proteins like what has been shown with LVAD support.  In all cases, 
calsequestrin was used to normalize the data because protein levels have consistently 
been shown not to change in heart failure.27,53,83 
 Both SERCA/CALQ and NCX/CALQ protein levels showed no differences 
among groups in this study.  The expected changes in failing and LVAD-supported hearts 
were not replicated, making comparisons between the non-failing group and F + BF 
group difficult to interpret.  In a way, the lack of significant differences in 
SERCA/CALQ and NCX/CALQ protein levels between non-failing and F + BF hearts 
supports our hypothesis, however after consideration of the possible reasons why the 
expected changes were not replicated, it is unlikely that such a suggestion can be made. 
 What has been noticed in our laboratory is that calcium cycling protein 
measurements are variable based on the patient sample selected.  Sometimes a group of 
patients exhibits the expected differences are shown, and sometimes they do not.  This is 
worth exploring further since many gene therapy trials have begun to alter levels of 
calcium cycling proteins based on these “known changes” that we no longer see 
consistently in the laboratory.   
The calcium cycling protein that did show changes across groups in this study 
was the ryanodine receptor.  RYR/CALQ levels decreased significantly in the failing 
group relative to the non-failing group, and a further decrease was shown in the F + 
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LVAD and F + BF groups.  Because there is no consensus in the literature with respect to 
RYR protein expression51, the results of the current study are open to interpretation.  If 
RYR protein levels are depressed in heart failure, this would mean less calcium would be 
released from the sarcoplasmic reticulum and into the cytosol to bind the myofilaments 
and cause cardiomyocyte contraction.  The fact that RYR/CALQ levels do not recover in 
LVAD-supported hearts is counterintuitive, as one might imagine RYR receptors would 
be normalized in this group in order to improve muscle contractility. 
 Combined with the absence of changes in SERCA/CALQ and NCX/CALQ 
protein levels, a decrease in RYR/CALQ level does not support the normalization of 
contractile function that was shown in the F + BF group.  Because it is a calcium release 
channel, decreased RYR protein would keep calcium from being released from the 
sarcoplasmic reticulum (SR).  Without being released into the cytosol where it can bind 
to myofilaments and enhance myocardial contractility, calcium is of no use in the SR.  
Perhaps calcium is released through the IP3 receptor which means that activation of the 
odd-numbered muscarinic receptors would be necessary.  Without measuring muscarinic 
receptor subtypes, one can only speculate that the odd-numbered receptors play a greater 
role in releasing calcium into the cytosol and thereby improving contractile function in 
the F + BF group.  The only other study that measured muscarinic receptor density in 
non-failing, failing and LVAD-supported hearts also measured muscarinic receptor 
subtypes and showed that the percentage of odd-numbered muscarinic receptors goes up 
in the F + LVAD group42, supporting this idea as a possible mechanism in the current 
study for the F + BF group.  
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4.5 Correlation Data 
In an attempt to determine whether patients who were successful with biofeedback 
were the same patients who showed biological changes in the heart, each biofeedback 
variable that changed was correlated with the four biological variables that changed or 
were variable including the developed tension response to ISO, beta-adrenergic receptor 
density, muscarinic receptor density, and RYR/CALQ protein concentration. 
Although no significant relationships were found, two correlations included a data 
point that was outside the 95% confidence interval.  This point was found to be from the 
same patient in both data sets, the only patient with congenital heart failure in this patient 
cohort.  Because the mechanism of congenital heart failure may be different from dilated 
and ischemic cardiomyopathies, this point was removed from both data sets, and 
significant relationships emerged.   
Patients who were breathing at slower rates in session eight of the biofeedback-
assisted stress management training protocol showed greater expression of RYR protein 
levels.  Even though overall RYR protein expression was lower in the F + BF group 
relative to the non-failing group, this suggests that success with respiration training may 
help to normalize RYR protein level. 
The second significant correlation that emerged showed that patients who showed a 
greater percent decrease in respiration rate also showed the greatest developed tension 
response to isoproterenol.  This suggests that breathing at lower rates may decrease 
background sympathetic nervous system arousal such that the cardiovascular system can 
respond to increases in sympathetic activity (demand). 
The numbers of days patients waited between their last session of the biofeedback- 
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assisted stress management training protocol and their date of heart transplantation was 
also correlated with the four biological variables listed above, and no significant 
relationships were found.  
 
4.6 Summary 
With improvements like a decrease in respiration rate and an increase in heart rate 
variability, end-stage heart failure patients in this study were certainly able to use 
biofeedback to learn how to modify certain physiologic variables.  Although no control 
group was included for comparison, it is possible that biofeedback-assisted stress 
management training may have improved quality of life and clinical course in some 
patients in the cohort.  Many patients asked to continue receiving biofeedback after their 
participation in the study had ended, and sometimes cardiologists requested that we enroll 
one of their patients in the study because they felt it would be beneficial to them.  One 
patient’s medical chart documents her comments specifically regarding participation in 
this biofeedback study.  She says, “I thought it was helpful.  When going into an anxiety 
state, I can get into a calm place.  It helps with negative thoughts.”  When asked whether 
or not biofeedback has lost its effectiveness five months after the study, she said no. 
On the biological side, contractile response to beta-adrenergic stimulation recovered 
in some patients, and other patients showed recovery in beta-adrenergic receptor density.  
Because the expected results with respect to calcium cycling proteins were not exhibited, 
it is unclear what the lack of differences between SERCA and NCX expression in NF and 
F + BF hearts actually means.  RYR protein expression was shown to be decreased in the 
F + BF group which may have something to do with the recovery of muscarinic receptor 
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density also shown in this group, however further studies must be done in order to 
explore the mechanisms involved in the biological changes shown in this study. 
   
4.7 Future Directions 
One question that was left unanswered in this study is whether or not patients 
incorporated the relaxation and stress management skills into their daily lives.  It is 
possible that patients were able to control their physiology when prompted to do so 
during biofeedback training, and a follow-up measurement at some later date after the 
conclusion of the study would provide some insight into the endurance of biofeedback-
assisted stress management training.  
Considering the recent work by Kevin Tracey that showed decreased vagal control of 
the heart can have pro-inflammatory consequences that exacerbate the heart failure 
condition57,113, it might also be interesting to measure pro-inflammatory cytokines before 
and after biofeedback training.  Other questions one could ask are (1) Does biofeedback 
decrease transplant recovery time? or (2) Does biofeedback decrease transplant rejection?  
In order to measure parasympathetic nervous system activity to correlate with these 
endpoints would be to use frequency domain analyses of heart rate variability. 
 Over the course of this study, it has become clear that the end-stage heart failure 
population is very challenging to study, and it would be interesting to see if biofeedback-
assisted stress management training can be effective in patients with earlier stages of 
cardiovascular disease.  Gender and diagnosis-specific differences may also be worth 
exploring in the future as the potential for biofeedback-assisted stress management 
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